[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 560
1. Walvekar RR, Kane SV, D'Cruz AK: Collision tumor of the thyroid: follicular variant of papillary carcinoma and squamous carcinoma. World J Surg Oncol; 2006;4:65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of the thyroid: follicular variant of papillary carcinoma and squamous carcinoma.
  • BACKGROUND: Collision tumors of the thyroid gland are a rare entity.
  • We present a case of a follicular variant of papillary carcinoma and squamous carcinoma in the thyroid.
  • To the best of our knowledge, this is the first documentation of a collision tumor with a papillary carcinoma and a squamous carcinoma within the thyroid gland.
  • CASE PRESENTATION: A 65 year old woman presented with a large thyroid swelling of 10 years duration and with swellings on the back and scalp which were diagnosed to be a follicular variant of papillary thyroid carcinoma with metastasis.
  • Clinical examination, radiology and endoscopy ruled out any other abnormality of the upper aerodigestive tract.
  • The histopathology revealed a collision tumor with components of both a follicular variant of papillary carcinoma and a squamous carcinoma.
  • Adjuvant radio iodine therapy directed toward the follicular derived component of the thyroid tumor and external beam radiotherapy for the squamous component was planned.
  • CONCLUSION: Collision tumors of the thyroid gland pose a diagnostic as well as therapeutic challenge.
  • The origins of squamous cancer in the thyroid gland must be established to support the true evolution of a collision tumor and to plan treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1997 Nov;174(5):474-6 [9374217.001]
  • [Cites] Eur J Endocrinol. 1997 Sep;137(3):267-9 [9330591.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):574-8 [9028370.001]
  • [Cites] J Surg Oncol. 1988 Nov;39(3):175-8 [3184953.001]
  • [Cites] Head Neck Surg. 1984 Jul-Aug;6(6):1035-42 [6469655.001]
  • [Cites] Endocr Pract. 1999 Mar-Apr;5(2):69-71 [15251691.001]
  • [Cites] Head Neck. 2004 Jul;26(7):637-41 [15229907.001]
  • [Cites] Diagn Cytopathol. 2002 Oct;27(4):227-31 [12357501.001]
  • [Cites] Yonsei Med J. 2002 Jun;43(3):381-4 [12089749.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Apr;128(4):461-2; discussion 463-4 [11926928.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Oct;55(4):543-8 [11678839.001]
  • [Cites] Histopathology. 2001 Sep;39(3):279-86 [11532039.001]
  • [Cites] Arch Pathol Lab Med. 2001 Apr;125(4):541-3 [11260633.001]
  • [Cites] Eur J Surg Oncol. 1999 Dec;25(6):606-9 [10556008.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):662-4 [15917423.001]
  • (PMID = 16984659.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1622750
  •  go-up   go-down


2. Bukhari U, Sadiq S, Kehar SI: Differential expression of CK 19 in follicular adenoma, well-differentiated tumour of uncertain malignant potential (WDT-UMP) and follicular variant of papillary carcinoma. J Pak Med Assoc; 2009 Jan;59(1):15-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of CK 19 in follicular adenoma, well-differentiated tumour of uncertain malignant potential (WDT-UMP) and follicular variant of papillary carcinoma.
  • OBJECTIVE: To see the expression of cytokeratin 19, a proven helpful marker for the differential diagnosis of neoplastic follicular patterned lesions of thyroid.
  • On the basis of the recent recommendations by Chemobyl Pathologists Group, encapsulated follicular patterned lesions with questionable nuclear changes were categorized as well - differentiated tumours of uncertain malignant potential (WDT-UMP).
  • Formalin fixed paraffin embedded tissues of follicular adenoma, WDT-UMP and follicular variant of papillary carcinoma were obtained for CK 19 immunostaining.
  • RESULTS: All (16) cases of follicular adenoma were negative for CK19.
  • There were 43 cases of follicular variant of papillary carcinoma with 4+ CK 19 positivity, 14 were 3+ positive and 3 were 2+ positive.
  • CONCLUSION: CK19 is a good and useful diagnostic marker for differential diagnosis of follicular adenoma, WDT-UMP and follicular variant of papillary carcinoma.
  • [MeSH-major] Adenoma / physiopathology. Carcinoma, Papillary / physiopathology. Keratin-19

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19213370.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Keratin-19
  •  go-up   go-down


3. Jung YH, Kang MS: Composite follicular variant of papillary carcinoma and mucoepidermoid carcinoma of thyroid gland: a case report. J Korean Med Sci; 2010 Nov;25(11):1683-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite follicular variant of papillary carcinoma and mucoepidermoid carcinoma of thyroid gland: a case report.
  • A 50-yr-old male presented a thyroid mass with dysphasia and hoarseness.
  • Pathologically, the tumor had two distinct tumor components with intermingled areas: follicular variant of papillary carcinoma and mucoepidermoid carcinoma.
  • Mucoepidermoid carcinoma composed of columnar cells, mucocytes, and squamoid cells showing solid and cystic lesion.
  • By immunohistochemistry, columnar cells and squamoid cells in mucoepidermoid carcinoma were positive for cytokeratin but negative for thyroglobulin, TTF-1 and calcitonin.
  • Tumor cells of papillary carcinoma are positive for TTF-1, thyroglobulin but negative for CEA, calcitonin and p63.
  • [MeSH-major] Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Jul;13(7):802-7 [10912941.001]
  • [Cites] Am Surg. 2001 Oct;67(10):979-83 [11603557.001]
  • [Cites] Mod Pathol. 2003 Jan;16(1):43-8 [12527712.001]
  • [Cites] Dis Esophagus. 2003;16(3):265-7 [14641323.001]
  • [Cites] J Pathol. 2004 Feb;202(2):247-51 [14743508.001]
  • [Cites] Cancer. 1977 Jan;39(1):210-4 [832236.001]
  • [Cites] Histopathology. 1984 Sep;8(5):847-60 [6083973.001]
  • [Cites] J Pathol. 1988 Jul;155(3):191-200 [3045277.001]
  • [Cites] Arch Pathol Lab Med. 1990 Oct;114(10):1049-52 [2222147.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1209-15 [7573680.001]
  • [Cites] Hum Pathol. 1995 Oct;26(10):1099-108 [7557943.001]
  • [Cites] Surg Today. 1995;25(9):843-7 [8555707.001]
  • [Cites] Eur J Surg Oncol. 1995 Dec;21(6):692 [8631425.001]
  • [Cites] Pathol Res Pract. 1995 Dec;191(12):1214-21 [8927569.001]
  • [Cites] Am Surg. 1998 Apr;64(4):307-11 [9544139.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(3):291-3 [9641234.001]
  • [Cites] Am J Otolaryngol. 2005 Mar-Apr;26(2):138-41 [15742270.001]
  • [Cites] Pathol Int. 2008 Nov;58(11):741-4 [18844942.001]
  • [Cites] Lung Cancer. 2009 Jan;63(1):159-60 [18992960.001]
  • [Cites] Hum Pathol. 2009 Jul;40(7):1029-35 [19269016.001]
  • (PMID = 21060764.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 68238-35-7 / Keratins; 9007-12-9 / Calcitonin; 9010-34-8 / Thyroglobulin
  • [Other-IDs] NLM/ PMC2967012
  • [Keywords] NOTNLM ; Carcinoma, Mucoepidermoid / Carcinoma, Papillary / Solid Cell Nests / Thyroid Gland
  •  go-up   go-down


Advertisement
4. Lee JM, Kim JW, Song JY, Lee JK, Lee NW, Kim SH, Lee KW: Adenocarcinoma arising in mature cystic teratoma: a case report. J Gynecol Oncol; 2008 Sep;19(3):199-201

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma arising in mature cystic teratoma: a case report.
  • Malignant transformation of a benign cystic teratoma is a rare event, and adenocarcinoma is extremely rare, and distinguishing this malignant change from benign disease preoperatively is nearly impossible even by the use of radiological imaging or various tumor markers.
  • We present a case with thyroid papillary carcinoma of follicular variant arising from mature cystic teratoma removed by laparoscopic salpingo-oophorectomy followed by staging laparotomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2007 Jul;15(3):318-20 [17652549.001]
  • [Cites] Pathol Res Pract. 2006;202(7):531-5 [16713128.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):140-4 [16445624.001]
  • [Cites] Obstet Gynecol Surv. 1957 Dec;12(6):793-830 [13493921.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1326-33 [9788856.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2249-55 [9610706.001]
  • [Cites] Obstet Gynecol Surv. 2000 Dec;55(12):738-45 [11128910.001]
  • [Cites] Gynecol Oncol. 1992 Jun;45(3):248-53 [1319383.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1988 Dec;29(4):329-38 [3229546.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):597-9 [15297213.001]
  • [Cites] Pathol Int. 2004 Feb;54(2):139-43 [14720146.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):338-41 [12893196.001]
  • [Cites] Arch Gynecol Obstet. 2002 Dec;267(2):107-9 [12439559.001]
  • [Cites] Arch Pathol Lab Med. 1993 Jun;117(6):647-9 [8503739.001]
  • (PMID = 19471568.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676465
  • [Keywords] NOTNLM ; Adenocarcinoma / Malignant transformation / Mature cystic teratoma / Tumor marker
  •  go-up   go-down


5. Rekhi B, Badhe RR, Desouza MA, Chaukar D, D'Cruz AK, Arya S, Kane SV: A unique RET EXON 11 (G691S) polymorphism in an Indian patient with a collision tumor of the thyroid. Diagn Pathol; 2007;2:39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A unique RET EXON 11 (G691S) polymorphism in an Indian patient with a collision tumor of the thyroid.
  • BACKGROUND: Collision tumors of the thyroid are rare, with occasional reports dealing with their genetic analysis.
  • Radiological examination revealed nodular masses in the left lobe of her thyroid, along with one in the isthmus, extending into the right lobe and associated with enlarged neck nodes.
  • FNAC from the left thyroid showed features of medullary carcinoma.
  • On total thyroidectomy, 2 distinct tumor nodules were identified in the left lobe with another in the isthmus, showing features of medullary carcinoma (MTC), papillary carcinoma and follicular variant of papillary carcinoma, respectively, accompanied with nodal metastasis.
  • RET gene analysis of the patient, her 2 daughters and a grandson revealed a unique G691S polymorphism on Exon 11.
  • CONCLUSION: This unique case of a collision tumor of thyroid, including component of an MTC deals with the value of RET gene analysis and therapeutic implications in the index case and in family members.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1814-7 [12702567.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1929-36 [12085189.001]
  • [Cites] Endocr Pathol. 2003 Fall;14(3):269-76 [14586073.001]
  • [Cites] Endocr Pathol. 2004 Spring;15(1):83-8 [15067180.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3579-84 [15240649.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):511-21 [15277225.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):281-9 [15947103.001]
  • [Cites] Pathol Int. 2006 Feb;56(2):84-8 [16445820.001]
  • [Cites] Semin Oncol. 1987 Sep;14(3):306-14 [2888195.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):908-11 [2914297.001]
  • [Cites] J Clin Pathol. 1966 Mar;19(2):103-13 [5909693.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jan;78(1):114-20 [7904611.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):375-6 [7906866.001]
  • [Cites] Hum Mol Genet. 1993 Jul;2(7):851-6 [8103403.001]
  • [Cites] Am J Surg Pathol. 1996 Feb;20(2):245-50 [8554115.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Mar;44(3):249-57 [8729519.001]
  • [Cites] Pathologica. 1997 Jun;89(3):317-22 [9270266.001]
  • [Cites] Histopathology. 1992 Oct;21(4):380-2 [1398541.001]
  • [Cites] Surg Today. 2001;31(4):317-21 [11321340.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):299-304 [11979448.001]
  • [Cites] Endocrinology. 2002 Jun;143(6):2025-8 [12021165.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1413-8 [10550294.001]
  • (PMID = 17939859.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2164940
  •  go-up   go-down


6. Paşcanu I, Borda A, Bănescu C: Thyroid nodule with Hashimoto thyroiditis in childhood - a challenging experience. Rom J Morphol Embryol; 2008;49(4):541-5
Genetic Alliance. consumer health - Hashimoto's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid nodule with Hashimoto thyroiditis in childhood - a challenging experience.
  • Fine-needle aspiration biopsy (FNAB) of the thyroid, although not perfect, is considered currently the best preoperative method in establishing malignancy in a thyroid nodule.
  • We report the case of an 8-year-old girl with a thyroid mass in the right thyroid lobe.
  • Endocrine investigations revealed subclinical hypothyroidism and high titer of anti-thyroid peroxidase antibodies.
  • Fine Needle Aspiration Biopsy (FNAB) of the right side of the thyroid gland, where on thyroid ultrasonography (US) a poorly defined iso-/hypoechoic nodule with irregular margins was detected, revealed a background of lymphocytes and plasma cells mixed with follicular cells with reactive changes.
  • Right lobectomy was performed and the pathology report shows papillary carcinoma, follicular variant predominantly with components of insular growth.
  • [MeSH-major] Hashimoto Disease / diagnosis. Thyroid Nodule / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050804.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


7. Fonseca E, Soares P, Cardoso-Oliveira M, Sobrinho-Simões M: Diagnostic criteria in well-differentiated thyroid carcinomas. Endocr Pathol; 2006;17(2):109-17
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic criteria in well-differentiated thyroid carcinomas.
  • The criteria used for the differential diagnosis of well-differentiated thyroid tumors derived from follicular cells are reviewed taking into account the architectural characteristics together with the immunohistochemical and molecular features.
  • The review is focused on follicular carcinoma, papillary carcinoma, follicular variant of papillary carcinoma, and oncocytic (Hürthle cell) tumors, as well as on the recently described borderline lesions: follicular and well-differentiated tumors of uncertain malignant potential, and well-differentiated carcinoma, not otherwise specified.
  • [MeSH-major] Carcinoma / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Follicular / classification. Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Papillary / classification. Adenocarcinoma, Papillary / diagnosis. Adenoma / classification. Adenoma / diagnosis. Diagnosis, Differential. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17159243.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


8. Burningham AR, Krishnan J, Davidson BJ, Ringel MD, Burman KD: Papillary and follicular variant of papillary carcinoma of the thyroid: Initial presentation and response to therapy. Otolaryngol Head Neck Surg; 2005 Jun;132(6):840-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary and follicular variant of papillary carcinoma of the thyroid: Initial presentation and response to therapy.
  • INTRODUCTION: The 2 most common histologic variants of papillary carcinoma are pure papillary carcinoma (PTC) and follicular variant of papillary thyroid carcinoma (FVPTC).
  • The purpose of this study is to compare the presentation and short-term response to therapy of these variants and to determine if FVPTC is a more aggressive form of thyroid cancer that warrants intensive therapy.
  • RESULTS: Of 160 patients with papillary thyroid carcinoma included, 114 (71%) had PTC and 46 (29%) had FVPTC.
  • [MeSH-major] Carcinoma, Papillary / surgery. Carcinoma, Papillary, Follicular / surgery. Thyroid Neoplasms / surgery. Thyroidectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944551.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


9. Sobrinho-Simões M, Preto A, Rocha AS, Castro P, Máximo V, Fonseca E, Soares P: Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch; 2005 Nov;447(5):787-93
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathology of well-differentiated thyroid carcinomas.
  • The newly discovered molecular features of well-differentiated thyroid carcinomas derived from follicular cells are reviewed, within the frame of the 2004 WHO classification of thyroid tumours, under the following headings: "Follicular carcinoma", "Papillary carcinoma", "Follicular variant of papillary carcinoma" and "Hürthle cell tumours".
  • A particular emphasis is put on the meaning of PAX8-PPARgamma rearrangements, RAS and BRAF mutations, and deletions and mutations of mitochondrial genes and of nuclear genes encoding for mitochondrial enzymes, for thyroid tumorigenesis.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Papillary, Follicular / genetics. Gene Rearrangement. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16189702.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Number-of-references] 70
  •  go-up   go-down


10. Eszlinger M, Paschke R: Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol; 2010 Jun 30;322(1-2):29-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns.
  • Fine-needle aspiration biopsy (FNAB) is currently the most sensitive and specific tool for the presurgical differential diagnosis of thyroid malignancy, but has also substantial limitations.
  • While approximately 75% of FNAB reveal benign lesions and 5% already cytologically prove malignancy, up to 20% of FNAB show follicular proliferation for which follicular adenoma, follicular carcinoma, and follicular variant of papillary carcinoma can only be distinguished histologically, thus requiring thyroid surgery.
  • However, new biomarkers that might improve the accuracy of FNAB come along with the discovery of more and more details of the molecular etiology of thyroid tumors.
  • Nevertheless, the application of molecular markers will significantly improve thyroid tumor diagnosis and thus it will help to prevent unnecessary surgeries and it will also help to guide mutation-specific targeted therapies.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis. Thyroid Nodule / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20083161.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 123
  •  go-up   go-down


11. Zhao J, Leonard C, Brunner E, Gemsenjäger E, Heitz PU, Odermatt B: Molecular characterization of well-differentiated human thyroid carcinomas by cDNA arrays. Int J Oncol; 2006 Nov;29(5):1041-51
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of well-differentiated human thyroid carcinomas by cDNA arrays.
  • Well-differentiated papillary and follicular thyroid carcinomas are the two most common types of thyroid cancer.
  • Although cancerous cells in both types phenotypically resemble the epithelial follicular cell, the tumors display different histological characteristics and clinical outcomes.
  • Gene expression profiling of 46 thyroid samples (16 papillary carcinomas, 13 follicular carcinomas and 17 normal thyroid specimens) was performed by using high-density human UniGene cDNA arrays.
  • The majority of genes with altered expression were found in both papillary and follicular carcinomas, reflecting a close relationship between the two tumor types.
  • However, 123 genes consisting of 45 known and 78 unknown genes were shown to be differentially expressed between papillary and follicular carcinomas.
  • Follicular variants of papillary carcinoma, clustered together with classical papillary carcinoma, could be differentiated from follicular carcinoma.
  • Our study revealed a set of genes differentiating follicular carcinoma from classical papillary carcinoma and follicular variant.
  • The data generated in this study could serve as a useful source for further investigation of pathways of papillary and follicular differentiation of thyroid cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Carcinoma, Papillary / genetics. Genes, Neoplasm. Thyroid Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17016634.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


12. Hunt J: Understanding the genotype of follicular thyroid tumors. Endocr Pathol; 2005;16(4):311-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding the genotype of follicular thyroid tumors.
  • Tumors of the thyroid with a follicular growth pattern are controversial and can be diagnostically challenging for the pathologist.
  • This group of tumors includes both follicular derived lesions (adenomas and carcinomas) and papillary carcinoma (follicular variant of papillary carcinoma).
  • In the past several decades, however, several important molecular markers have been identified that may be unique to different types of thyroid carcinomas.
  • However, with increasing availability of molecular testing for the general pathologist, a molecular testing panel used in conjunction with the H&E morphology and immunohistochemical stains may become useful in the clinical setting for the diagnosis of thyroid tumors.
  • [MeSH-major] Carcinoma, Papillary, Follicular / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627918.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


13. Jeh SK, Jung SL, Kim BS, Lee YS: Evaluating the degree of conformity of papillary carcinoma and follicular carcinoma to the reported ultrasonographic findings of malignant thyroid tumor. Korean J Radiol; 2007 May-Jun;8(3):192-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluating the degree of conformity of papillary carcinoma and follicular carcinoma to the reported ultrasonographic findings of malignant thyroid tumor.
  • OBJECTIVE: We wanted to evaluate the degree of conformity of papillary carcinoma and follicular carcinoma to the reported ultrasonographic findings of malignant thyroid tumor.
  • MATERIALS AND METHODS: Between January 2003 and December 2004, fine needle aspiration biopsy was performed in 1,036 patients with palpable and nonpalpable thyroid lesions.
  • We retrospectively reviewed the ultrasonographic findings of patients with papillary carcinomas (n = 127) and follicular carcinomas (n = 23) that were proven by operation or fine needle aspiration biopsy.
  • We analyzed the ultrasonographic findings of these nodules based on the reported ultrasonographic findings of malignant thyroid tumor: hypoechogenicity, a taller than wide orientation, a microlobulated or irregular margin, a thick hypoechoic rim (halo sign), microcalcification and cystic change.
  • RESULTS: The echogenicity was hypoechoic in 72.4% (92/127) of the papillary carcinomas, but it was isoechoic in 65.2% (15/23) of the follicular carcinomas (p < 0.001).
  • The nodule shape was tall or round in 74.1% of the papillary carcinomas, but it was flat in 72.7% of the follicular carcinomas (p < 0.001).
  • The tumor margin was microlobulated or irregular in 92.9% of the papillary carcinomas and in 60.9% of the follicular carcinomas (p < 0.001).
  • A hypoechoic rim was seen in 26% of the papillary carcinomas (thin rim: 13.4%, thick rim: 12.6%) and in 86.6% of the follicular carcinomas (thin rim: 39.1%, thick rim: 47.8%, p < 0.001).
  • Microcalcifications were demonstrated in 33.9% of the papillary carcinomas and in none of the cases of follicular carcinoma (p < 0.001).
  • A solid mass without cystic change were seen in 98.4% of the papillary carcinomas and in 82.6% of the follicular carcinomas (p < 0.001).
  • CONCLUSION: The previously reported ultrasonography findings of malignant thyroid tumor are in conformity with most of the papillary carcinomas, but not with follicular carcinomas.
  • The current ultrasonographic features for thyroid malignancy should be cautiously applied as the indication for needle aspiration biopsy so that follicular carcinomas are not missed by too narrow and strict biopsy criteria.
  • [MeSH-major] Adenocarcinoma, Follicular / ultrasonography. Carcinoma, Papillary / ultrasonography. Thyroid Neoplasms / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Calcinosis / ultrasonography. Female. Humans. Male. Middle Aged. Retrospective Studies. Thyroid Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2004 Dec;28(12):1261-5 [15517496.001]
  • [Cites] Thyroid. 2005 Mar;15(3):251-8 [15785244.001]
  • [Cites] Endocr J. 2005 Apr;52(2):207-12 [15863949.001]
  • [Cites] Radiology. 2005 Dec;237(3):794-800 [16304103.001]
  • [Cites] AJR Am J Roentgenol. 2002 Mar;178(3):687-91 [11856699.001]
  • [Cites] J Ultrasound Med. 2004 Nov;23(11):1455-64 [15498910.001]
  • [Cites] J Ultrasound Med. 2003 Feb;22(2):127-31; quiz 132-4 [12562117.001]
  • [Cites] J Ultrasound Med. 2003 Oct;22(10):1027-31 [14606557.001]
  • [Cites] J Ultrasound Med. 2003 Oct;22(10):1083-90 [14606565.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Jan;60(1):21-8 [14678283.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):1941-6 [11994321.001]
  • (PMID = 17554185.001).
  • [ISSN] 1229-6929
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2627417
  •  go-up   go-down


14. Coyne C, Nikiforov YE: RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii. Endocr Pathol; 2010 Jun;21(2):144-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii.
  • Struma ovarii is an ovarian mature teratoma composed exclusively or predominantly of thyroid tissue.
  • Malignant transformation of struma ovarii is rare and poorly understood, although this process is thought to be similar to carcinogenesis in malignant tumors of differentiated thyroid tissue originating in the thyroid gland.
  • Genetic alterations in the mitogen-activated protein kinase pathway, including mutations of BRAF, RAS, and RET genes, have been implicated in the development of differentiated thyroid carcinoma arising in the thyroid gland.
  • She proceeded to ovarian cystectomy post-delivery, with pathologic examination detecting a papillary thyroid carcinoma, follicular variant, arising in a cystic teratoma.
  • This is the first report of RAS mutation detected in the follicular variant of papillary carcinoma arising in a struma ovarii.
  • It provides evidence that tumors developing in this setting involve molecular mechanisms similar to those implicated in tumors developing in the thyroid gland.
  • [MeSH-major] Adenocarcinoma, Papillary / genetics. Neoplasms, Multiple Primary / genetics. Ovarian Neoplasms / genetics. Struma Ovarii / genetics. Thyroid Neoplasms / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898969.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


15. Mori K, Kitazawa R, Kondo T, Kitazawa S: Lung adenocarcinoma with micropapillary component presenting with metastatic scrotum tumor and cancer-to-cancer metastasis: A case report. Cases J; 2008;1(1):162

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinoma with micropapillary component presenting with metastatic scrotum tumor and cancer-to-cancer metastasis: A case report.
  • A scrotal skin biopsy revealed a poorly-differentiated adenocarcinoma, immunohistochemically positive for cytokeratin 7 (CK7) and for thyroid transcription factor 1 (TTF-1), and negative for CK20.
  • At autopsy, a consolidating lesion with vague margin was noted in the left lung as well as a well-circumscribed nodule in the right lobe of the thyroid.
  • Histopathologically, pulmonary lesion was adenocarcinoma with a micropapillary component.
  • On the other hand, thyroid tumor was diagnosed as a follicular variant of papillary carcinoma with foci of micropapillary adenocarcinoma.
  • Positive immunohistochemistry for surfactant protein on micoropapillary component was useful to confirm that micropapillary component was of lung adenocarcinoma origin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 2005 Jul-Aug;113(7-8):550-4 [16086826.001]
  • [Cites] Pathol Res Pract. 1994 Aug;190(7):668-74 [7808965.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):189-94 [10981870.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):319-26 [15104294.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):358-64 [11859208.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):297-303 [15505530.001]
  • (PMID = 18801198.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2556662
  •  go-up   go-down


16. Ito Y, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Nakamura Y, Kakudo K, Kuma K, Miyauchi A: Caveolin-1 and 14-3-3 sigma expression in follicular variant of thyroid papillary carcinoma. Pathol Res Pract; 2005;201(8-9):545-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1 and 14-3-3 sigma expression in follicular variant of thyroid papillary carcinoma.
  • There are two prominent types of thyroid carcinoma, papillary carcinoma (PC) and follicular carcinoma (FC) arising from thyroid follicular cells, which have different biological characteristics.
  • The follicular variant of papillary carcinoma (FVPC) has a structure similar to FC, although it is classified as a subtype of PC.
  • These findings suggest that caveolin-1 and 14-3-3 sigma positively or negatively regulate the development of FVPC but not that of FC, reflecting the difference of biological characteristics of these two types of carcinoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Papillary, Follicular / metabolism. Caveolins / metabolism. Exonucleases / metabolism. Neoplasm Proteins / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] 14-3-3 Proteins. Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Caveolin 1. Exoribonucleases. Humans. Immunoenzyme Techniques

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259106.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / CAV1 protein, human; 0 / Caveolin 1; 0 / Caveolins; 0 / Neoplasm Proteins; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human
  •  go-up   go-down


17. Sato T, Harao M, Nakano S, Jotsuka T, Suda N, Yamashita J: Circulating tumor cells detected by reverse transcription-polymerase chain reaction for carcinoembryonic antigen mRNA: distinguishing follicular thyroid carcinoma from adenoma. Surgery; 2005 May;137(5):552-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cells detected by reverse transcription-polymerase chain reaction for carcinoembryonic antigen mRNA: distinguishing follicular thyroid carcinoma from adenoma.
  • BACKGROUND: We prospectively tested whether circulating tumor cells could be detected in peripheral blood of patients with thyroid tumors by a reverse transcription-polymerase chain reaction (RT-PCR) to detect carcinoembryonic antigen (CEA) messenger RNA (mRNA).
  • METHODS: We assayed for CEA mRNA by RT-PCR in peripheral blood sampled before and 2 to 3 weeks after curative surgery for thyroid tumors in 121 patients.
  • RESULTS: No control samples were positive for CEA mRNA by RT-PCR.
  • Of 121 preoperative samples from patients with thyroid tumor, 6 were positive (5.0%).
  • Preoperative frequencies of CEA mRNA positivity in benign tumor, papillary carcinoma, follicular variant papillary carcinoma, minimally invasive follicular carcinoma, and widely invasive follicular carcinoma were 0%, 0%, 0%, 44.4% (4/9), and 50.0% (2/4), respectively.
  • Among positive patients only one, who had widely invasive follicular carcinoma, remained positive after surgery.
  • CONCLUSIONS: RT-PCR detection of tumor cells in preoperative blood often can distinguish malignant from benign follicular thyroid tumors.
  • [MeSH-major] Adenoma / metabolism. Carcinoembryonic Antigen / metabolism. Carcinoma / metabolism. Goiter, Nodular / metabolism. Neoplastic Cells, Circulating / metabolism. Thyroid Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15855928.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / RNA, Messenger
  •  go-up   go-down


18. Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM: Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol; 2007;18(1):1-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study.
  • Thyroid carcinomas with follicular phenotype have demonstrated changing patterns over 30 years (1973-2003) according to data from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.
  • Papillary carcinomas have significantly increased.
  • They accounted for 74% of all cases of thyroid cancers in 1973 and 87% in 2003.
  • During this period, the incidence rate of papillary carcinoma (including the follicular variant) increased by 189%, the rate of follicular carcinoma remained stable, and the rate of anaplastic carcinoma decreased by 22%.
  • The rate of the follicular variant of papillary carcinoma alone increased by 173%.
  • Thyroid cancer was more common in whites than in blacks and in females more than in males.
  • Papillary carcinomas rapidly increased during adolescence and reached a peak around age 52-56, then declined.
  • Follicular carcinomas increased steadily, but at a lower rate until age 80.
  • After 1988, both papillary and follicular carcinomas, less than 2 cm, increased at the same rate as carcinomas larger than 2 cm.
  • However, papillary carcinomas less than 2 cm were more common.
  • Overall, the 10-year relative survival rate was greater than 90% for blacks and whites with the exception of follicular carcinoma in blacks.
  • The 10-year relative survival rate for anaplastic carcinoma in patients over 40 years of age was 4.7%.
  • The decrease in incidence rate of anaplastic carcinoma may be the result of the successful treatment of papillary and follicular carcinomas.
  • [MeSH-major] Adenocarcinoma, Follicular. Carcinoma, Papillary. Thyroid Neoplasms


19. Ito Y, Miyauchi A: Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid. Endocr J; 2009;56(2):177-92
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid.
  • Differentiated thyroid carcinoma originates from thyroid follicular cells and is the most prominent malignancy of the endocrine organs.
  • There are two histological types of differentiated carcinoma, namely, papillary and follicular carcinoma.
  • According to reports from Western countries, papillary carcinoma comprises 85.3% of thyroid malignancies in whites, and 72.3% in blacks.
  • In Japan, a previous study showed that the prevalence of papillary carcinoma was 78.4% based on material registered between 1977 and 1986, but according to recent findings reported in 2004 by Japanese Society of Thyroid Surgeons (JSTS), papillary carcinoma accounted for as much as 93% of all thyroid carcinomas.
  • Papillary carcinoma frequently metastasizes to the regional lymph node and shows multicentricity in the thyroid gland.
  • Follicular carcinoma accounts for 10.9-20.5% of the patients in the United States.
  • In Japan, the prevalence of follicular carcinoma was reported to be 17.2%, but it decreased to 5% in a report by JSTS in 2004.
  • This carcinoma is only occasionally diagnosed preoperatively, because it is hard to discriminate follicular carcinoma from benign adenoma on imaging studies and cytologic findings.
  • In contrast to papillary carcinoma, follicular carcinoma more often metastasizes to distant organs than regional lymph nodes.
  • In Japan, the prevalence of papillary carcinoma increased and that of follicular carcinoma decreased between reports from 1977 to 1986 and that in 2004, which may be because follicular variant of papillary carcinoma was classified into follicular carcinoma in the previous results.
  • Generally, these carcinomas show an indolent character, but when the lesion dedifferentiates and becomes undifferentiated carcinoma, it displays very rapid growth with an adverse prognosis and is regarded even as the most aggressive malignancy among human solid carcinomas.
  • Indeed, it is most important for physicians to correctly distinguish high-risk cases from those with an indolent character, although how to evaluate the biological characteristics of thyroid carcinoma and how to identify high-risk cases remains highly controversial.
  • In this review, the methods of distinguishing high-risk cases and the appropriate therapeutic strategies for papillary and follicular carcinomas predominantly based on our experience are emphasized and our proposals for therapies including surgical treatment are demonstrated.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / therapy. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / pathology. Humans. Japan / epidemiology. Lymphatic Metastasis / pathology. Prognosis. Thyroidectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18703852.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 113
  •  go-up   go-down


20. Shapiro NL, Bhattacharyya N: Population-based outcomes for pediatric thyroid carcinoma. Laryngoscope; 2005 Feb;115(2):337-40
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based outcomes for pediatric thyroid carcinoma.
  • OBJECTIVES/HYPOTHESIS: The objective was to determine clinical features and clinical outcomes for pediatric thyroid carcinoma.
  • METHODS: The Surveillance, Epidemiology, and End Results database (1988-2000) was surveyed, extracting all cases of pediatric thyroid carcinoma.
  • Clinical features including age, gender, tumor type, tumor size, nodal disease, treatment modality, and survival variables were retrieved.
  • Cox regression analysis was conducted to determine prognostic factors affecting survival in pediatric carcinoma.
  • RESULTS: In all, 566 cases of thyroid carcinoma were extracted for the time period.
  • There were 378 cases of papillary carcinoma, 137 cases of follicular variant of papillary carcinoma, and 51 cases of follicular carcinoma.
  • The average tumor size was 2.6 cm, and 37.1% of patients presented with positive nodal disease.
  • Follicular carcinoma exhibited a slightly poorer survival that was statistically significant (P = .017) CONCLUSION: Pediatric thyroid carcinoma primarily affects girls.
  • Clinical features of tumor presentation are similar to those of adults with thyroid carcinoma.
  • However, overall survival for pediatric thyroid carcinoma is excellent, with few patients dying of disease.
  • [MeSH-major] Adenocarcinoma, Follicular / mortality. Carcinoma, Papillary / mortality. Thyroid Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Laryngoscope. 2006 Nov;116(11):2095; author reply 2095 [17075406.001]
  • (PMID = 15689762.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. French CA, Fletcher JA, Cibas ES, Caulfield C, Allard P, Kroll TG: Molecular detection of PPAR gamma rearrangements and thyroid carcinoma in preoperative fine-needle aspiration biopsies. Endocr Pathol; 2008;19(3):166-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular detection of PPAR gamma rearrangements and thyroid carcinoma in preoperative fine-needle aspiration biopsies.
  • The pathologic diagnosis of thyroid follicular tumors is difficult, particularly in preoperative fine-needle aspiration biopsies.
  • To investigate whether the molecular diagnosis of PPAR gamma rearrangements can detect thyroid carcinomas in fine-needle aspiration biopsies, we performed interphase fluorescence in situ hybridization on 24 thyroid fine-needle aspiration and 17 follow-up thyroidectomy specimens.
  • Two of the 24 fine-needle aspiration biopsies contained PPAR gamma rearrangements, and both were diagnosed suggestive of a thyroid follicular neoplasm by cytology.
  • The two corresponding thyroidectomies each contained PPAR gamma rearrangements in all tumor cells and, both were diagnosed follicular-patterned thyroid carcinomas-one a follicular carcinoma and the other a follicular variant of papillary carcinoma, the latter by majority of expert endocrine pathologists.
  • Our experiments demonstrate that PPAR gamma rearrangements can detect a subset of follicular-patterned thyroid carcinomas in preoperative thyroid fine-needle aspiration biopsies.
  • The ultimate utility of mutations such as PPAR gamma rearrangements in diagnosis of thyroid carcinoma must be proven by direct correlation of mutation status with thyroid tumor biology and not just with thyroid tumor morphology, a subjective and imprecise marker of clinical behavior.
  • The application of specific mutations to preoperative diagnosis of thyroid carcinoma is predicted to improve the accuracy and reduce the costs of treating patients with thyroid tumors.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Biomarkers, Tumor / genetics. PPAR gamma / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Endocr Pathol. 2008 Winter;19(4):299
  • (PMID = 18688583.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA75425
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PPAR gamma
  •  go-up   go-down


22. Wallander M, Layfield LJ, Jarboe E, Emerson L, Liu T, Thaker H, Holden J, Tripp S: Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts. Appl Immunohistochem Mol Morphol; 2010 May;18(3):231-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts.
  • CONTEXT: Despite the recognition of the follicular variant of papillary carcinoma of the thyroid (FVPTC) for over 50 years, reproducibility of this diagnostic category has remained poor.
  • Mutations in BRAF exon 15 were found in 25% (2/8) of cases with a 100% consensus diagnosis of FVPTC and 32% (6/19) of cases unanimously diagnosed as a type of papillary carcinoma (classic or follicular variant).
  • HBME-1 was expressed in 87.5% (7/8) of lesions with a 100% consensus diagnosis of FVPTC and 84.2% (16/19) of lesions with a unanimous diagnosis of a type of papillary carcinoma of the thyroid (classic or follicular variant).
  • HBME-1 expression when coupled with a BRAF mutation, results in 100% specificity but low sensitivity for the presence of papillary carcinoma of the thyroid including the follicular variant.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20042852.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HBME-1 antigen; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


23. Wang T, Jiang CX, Li Y, Liu X: [Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid]. Zhonghua Bing Li Xue Za Zhi; 2009 Dec;38(12):824-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid].
  • OBJECTIVE: To study the roles of matrix metalloproteinases-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), vascular endothelial growth factor (VEGF) and transforming growth factor β-1 (TGFβ-1) in differentiation, invasiveness and metastatic potential of papillary carcinoma and follicular carcinoma of thyroid.
  • METHODS: Eighty-five cases of papillary thyroid carcinoma and 59 cases of follicular thyroid carcinoma were enrolled into the study.
  • The positivity rates of MMP-9, TIMP-1, VEGF and TGFβ-1 in papillary thyroid carcinoma (83.5%, 81.2%, 90.6% and 75.3%, respectively) were similar to or lower than those in follicular thyroid carcinoma (93.2%, 86.4%, 89.9% and 78.0%, respectively).
  • The expression rates in papillary thyroid carcinoma with lymph node metastasis were also higher than those in tumors without lymph node metastasis.
  • The expression rates of MMP-9, VEGF and TGFβ-1 in poorly-differentiated follicular thyroid carcinoma were higher than those in well-differentiated follicular thyroid carcinoma.
  • In general, the expression of VEGF and MMP-9 was higher than that of TIMP-1 and TGFβ-1 in papillary thyroid carcinoma and follicular thyroid carcinoma.
  • CONCLUSIONS: Immunohistochemical detection of MMP-9, TIMP-1, VEGF and TGFβ-1 expression may carry clinical significance in evaluating the degree of differentiation, invasiveness, metastatic potential and prognosis of papillary thyroid carcinoma and follicular thyroid carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / pathology. Matrix Metalloproteinase 9 / metabolism. Thyroid Neoplasms / pathology. Tissue Inhibitor of Metalloproteinase-1 / metabolism. Transforming Growth Factor beta1 / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193458.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Transforming Growth Factor beta1; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


24. Kim SJ, Kim IJ, Kang YH, Kim YK: Characterization of follicular thyroid nodules at fine needle aspiration biopsy using double phase thallium-201 imaging: comparison of visual and semiquantitative analyses. Thyroid; 2006 Dec;16(12):1243-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of follicular thyroid nodules at fine needle aspiration biopsy using double phase thallium-201 imaging: comparison of visual and semiquantitative analyses.
  • OBJECTIVE: To compare visual and semiquantitative indices of double phase thallium-201 thyroid scintigraphy (DTS) for differentiation of malignant nodules by indeterminate fine needle aspiration biopsy (FNAB) results.
  • Early L/N was superior to delayed L/N and WR for the detection of malignant thyroid nodules.
  • CONCLUSION: Visual assessment had a limited value for differentiation of follicular nodules.
  • The early L/N was superior to delayed L/N and WR for the detection of malignant thyroid nodular lesions.
  • Visual analysis and semiquantitative indices of DTS could not differentiate follicular carcinoma and follicular variant of papillary thyroid cancer.
  • [MeSH-major] Thallium Radioisotopes. Thyroid Neoplasms / radionuclide imaging. Thyroid Nodule / radionuclide imaging
  • [MeSH-minor] Adenocarcinoma, Follicular / radionuclide imaging. Adolescent. Adult. Aged. Biopsy, Fine-Needle. Carcinoma, Papillary / radionuclide imaging. Carcinoma, Papillary, Follicular / radionuclide imaging. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17199434.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thallium Radioisotopes
  •  go-up   go-down


25. Rago T, Di Coscio G, Basolo F, Scutari M, Elisei R, Berti P, Miccoli P, Romani R, Faviana P, Pinchera A, Vitti P: Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hupsilonrthle cell thyroid lesions: results from a series of 505 consecutive patients. Clin Endocrinol (Oxf); 2007 Jan;66(1):13-20
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hupsilonrthle cell thyroid lesions: results from a series of 505 consecutive patients.
  • OBJECTIVE: The cytological patterns of follicular and Hupsilonrthle cell nodules are included among the indeterminate results of fine-needle aspiration cytology, because distinction between benign and malignant lesion can only be made on histological criteria.
  • The diagnostic value of atypia at cytology, clinical parameters and echographic patterns were examined to establish the risk of malignancy in 505 patients with follicular and Hupsilonrthle cell thyroid nodules at cytology.
  • RESULTS: Histological diagnosis of malignancy was carried out in 125 of 505 (25%) patients, the follicular variant of papillary carcinoma being the most frequent histotype.
  • Male gender, normal thyroid volume, single nodularity, nodule hypoechogenicity, size and blurred margins were associated with malignancy, although not significantly.
  • CONCLUSIONS: Twenty-five per cent of patients with a cytological result of follicular and Hupsilonrthle cell thyroid lesion had a final diagnosis of malignancy.
  • Only atypia at cytology and spot microcalcifications at thyroid ultrasound were significantly associated with malignancy.
  • Other clinical parameters and thyroid ultrasound patterns can be used to set up a clinical score useful for predicting the individual risk of malignancy before surgery.
  • [MeSH-major] Thyroid Gland / pathology. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / ultrasonography. Adenoma / pathology. Adenoma / ultrasonography. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / ultrasonography. Adult. Biopsy, Fine-Needle. Calcinosis / ultrasonography. Carcinoma, Medullary / pathology. Carcinoma, Medullary / ultrasonography. Carcinoma, Papillary, Follicular / pathology. Carcinoma, Papillary, Follicular / ultrasonography. Chi-Square Distribution. Cytodiagnosis. Diagnosis, Differential. Female. Humans. Hyperplasia. Male. Middle Aged. Predictive Value of Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17201796.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Torres-Cabala C, Bibbo M, Panizo-Santos A, Barazi H, Krutzsch H, Roberts DD, Merino MJ: Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol; 2006 Sep-Oct;50(5):518-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic identification of new biomarkers and application in thyroid cytology.
  • OBJECTIVE: To validate proteins identified by proteomics as potentially usable markers in thyroid pathology.
  • STUDY DESIGN: Frozen sections of thyroid tumors were manually micro-dissected and proteins extracted.
  • RESULTS: Galectin-3 was negative in benign lesions and positive in FNAB from papillary carcinoma (5 of 5), follicular variant of papillary carcinoma (1 of 4) and follicular carcinoma (1 of 2).
  • S100C was positive in some benign lesions: hyperplasia (2 of 4), goiter (1 of 3) and follicular adenoma (1 of 3), with predominantly nuclear pattern of staining.
  • Galectin-1 was negative in benign lesions and positive in follicular carcinoma (1 of 2), papillary carcinoma (2 of 5) and follicular variant of papillary carcinoma (1 of 4).
  • VDAC1 was detected in benign and malignant lesions, showing a strong positivity in follicular carcinomas.
  • Galectin-3, galectin-1 and S100C can be used to help in discriminating benign and malignant thyroid lesions.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Carcinoma, Papillary / diagnosis. Proteomics / methods. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17017437.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 1; 0 / Galectin 3; 0 / LGALS1 protein, human; 0 / S100 Proteins; 0 / VDAC1 protein, human; 146909-89-9 / S100A11 protein, human; EC 1.6.- / Voltage-Dependent Anion Channel 1
  •  go-up   go-down


27. Pezzolla A, Lattarulo S, Milella M, Barile G, Pascazio B, Ciampolillo A, Fabiano G, Palasciano N: [Incidental carcinoma in thyroid pathology: our experience and review of the literature]. Ann Ital Chir; 2010 May-Jun;81(3):165-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidental carcinoma in thyroid pathology: our experience and review of the literature].
  • [Transliterated title] Il carcinoma incidentale nella patologia tiroidea. La nostra esperienza e revisione della letteratura.
  • The diagnosis of incidental thyroid carcinoma in patients submitted to thyroidectomy for a benign disease is quite frequent.
  • A retrospective analysis was performed on 240 patients submitted to surgical intervention in order to establish the incidence of the carcinoma.
  • One hundred sixty five patients (68.75%) were affected by benign disease (132 multinodular goiter, 30 uninodular goiter, 2 Plummer and 1 Basedow) and 75 (31.25%) by carcinoma.
  • In 30 of 165 patients (18.2 %), affected by benign disease, occurred a histological diagnosis of thyroid carcinoma, (18 papillary carcinoma, 6 follicular carcinoma, 5 papillary carcinoma follicular variant and 1 oncocytic carcinoma).
  • In this study it's considered incidental thyroid carcinoma the one occurred in patients who never underwent FNA and there were no suspicious features in all exams that may suggest the presence of carcinoma.
  • Fifteen of the 30 incidental carcinoma (50%) were microcarcinomas; in the other 13, dimensions were more than 1 cm, but less than 2 cm in 9 cases.
  • Two patients had a synchronous carcinoma.
  • Actually these patients are still in a follow up program and no recurrency of disease is occasionally observed.
  • This study shows that the only way to put doubts on the real benignity of the disease is the fine needle aspiration; there are no other instruments that could let think about the occurrence of the carcinoma.
  • Moreover in the majority of cases the incidental carcinoma is a microcarcinoma, it doesn't reach significant volume, may be not centered by a FNAB, but in must cases it's not really biologically aggressive.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / pathology. Incidental Findings. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenoma, Oxyphilic / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Goiter, Nodular / pathology. Graves Disease / pathology. Humans. Incidence. Italy / epidemiology. Male. Middle Aged. Plummer-Vinson Syndrome / pathology. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21105480.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


28. Yuksel O, Kurukahvecioglu O, Ege B, Ekinci O, Aydin A, Poyraz A, Tezel E, Taneri F: The relation between pure papillary and follicular variant in papillary thyroid carcinoma. Endocr Regul; 2008 Mar;42(1):29-33
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relation between pure papillary and follicular variant in papillary thyroid carcinoma.
  • OBJECTIVE: Pure papillary thyroid carcinoma and the follicular variant papillary thyroid carcinoma are the most common subtypes of papillary thyroid carcinoma.
  • PATIENTS AND METHODS: Histopathological type of carcinoma was retrospectively revised in 199 patients who were then divided according to such type.
  • It was found that, although the tumor size of pure papillary thyroid carcinoma was smaller than that of follicular variant papillary thyroid carcinoma, lymph node metastases occurred more frequently when both subgroups were examined.
  • CONCLUSION: The pathological and clinical signs of pure papillary thyroid carcinoma and follicular variant papillary thyroid carcinoma were found similar.
  • According to these results, this study does not support the literature which claims that follicular variant papillary thyroid carcinoma is more aggressive than pure papillary thyroid carcinoma.
  • Moreover, it could be assumed that the number of patients who are diagnosed as pure papillary thyroid carcinoma may be higher when associated with Hashimoto's thyroiditis.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333702.001).
  • [ISSN] 1210-0668
  • [Journal-full-title] Endocrine regulations
  • [ISO-abbreviation] Endocr Regul
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / anti-thyroglobulin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


29. Patel MR, Bryson PC, Shores CG, Hart CF, Thorne LB, Deal AM, Zanation AM: Trefoil factor 3 immunohistochemical characterization of follicular thyroid lesions from tissue microarray. Arch Otolaryngol Head Neck Surg; 2009 Jun;135(6):590-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trefoil factor 3 immunohistochemical characterization of follicular thyroid lesions from tissue microarray.
  • OBJECTIVES: To characterize trefoil factor 3 (TFF3) expression in normal thyroid tissue samples compared with that in follicular adenoma, follicular carcinoma, and follicular variant of papillary thyroid carcinoma using immunohistochemistry on tissue microarrays.
  • DESIGN: Immunohistochemical analysis of 83 normal thyroid tissue and of 83 follicular neoplasms (26 follicular adenomas, 25 follicular variant of papillary thyroid carcinoma, 23 follicular thyroid carcinomas, and 9 papillary thyroid carcinomas) was performed using an antibody to TFF3 on tissue microarray sections composed of formalin-fixed, paraffin-embedded tissue samples.
  • PATIENTS: Thyroid tissue samples collected from patients over a 15-year period were obtained from the University of North Carolina Hospitals Division of Surgical Pathology archives.
  • MAIN OUTCOME MEASURES: Thyroid tissue samples were graded by a pathologist based on intensity of antibody staining and on percentage of cells stained.
  • Data were analyzed for semiquantitative differences in immunohistochemical intensity of antibody staining and in percentage of cells stained among normal thyroid tissue samples, follicular adenoma, follicular thyroid carcinoma, follicular variant of papillary thyroid carcinoma, and papillary thyroid carcinoma.
  • RESULTS: Semiquantitative analysis demonstrated that immunohistochemistry detects significant levels of TFF3 expression in normal thyroid tissue samples compared with that in follicular lesions based on intensity of antibody staining (P < .05).
  • Only follicular thyroid carcinoma demonstrated a significant reduction in percentage of cells stained compared with that in normal thyroid tissue samples (P = .03).
  • No significant differences in intensity of antibody staining or in the percentage of cells stained were noted among follicular adenoma, follicular thyroid carcinoma, follicular variant of papillary thyroid carcinoma, or papillary thyroid carcinoma.
  • CONCLUSIONS: Protein expression data validate gene expression findings that follicular neoplastic lesions have decreased expression of TFF3 compared with that in normal thyroid tissue samples.
  • These findings contribute to evidence suggesting that TFF3 may have a role in normal thyroid tissue function and that thyroid carcinomas may have reduced expression of TFF3, in contradistinction to other carcinomas that overexpress TFF3.
  • [MeSH-major] Adenoma / metabolism. Carcinoma, Papillary, Follicular / metabolism. Peptides / metabolism. Protein Array Analysis. Thyroid Gland / metabolism. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19528408.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides; 0 / TFF3 protein, human
  •  go-up   go-down


30. Cerilli LA, Frable WJ, Spafford MF: Anaplastic carcinoma of the thyroid with chondroblastoma features mimicking papillary carcinoma: a case report. Acta Cytol; 2007 Sep-Oct;51(5):825-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma of the thyroid with chondroblastoma features mimicking papillary carcinoma: a case report.
  • BACKGROUND: An unusual case of anaplastic carcinoma of the thyroid arising from a metastatic focus of papillary carcinoma.
  • CASE: The tumor affected a 69-year-old woman with a history of total thyroidectomy for papillary thyroid carcinoma 4 years previously.
  • A small, embedded focus of residual follicular variant of papillary carcinoma was present.
  • The patient died of disease 3 months later.
  • CONCLUSION: This "chondroblastoma" variant of anaplastic thyroid carcinoma has not been reported to date.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Papillary / pathology. Chondroblastoma / pathology. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Chondroblastoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910356.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


31. Giorgadze TA, Baloch ZW, Pasha T, Zhang PJ, Livolsi VA: Lymphatic and blood vessel density in the follicular patterned lesions of thyroid. Mod Pathol; 2005 Nov;18(11):1424-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic and blood vessel density in the follicular patterned lesions of thyroid.
  • The histologic distinction of follicular patterned lesions of thyroid, that is follicular adenoma, follicular carcinoma, and the follicular variant of papillary thyroid carcinoma can be extremely difficult.
  • The differential diagnostic criteria regarding nuclear features of papillary thyroid carcinoma are subjective, resulting in high interobserver variability.
  • Although papillary thyroid carcinoma metastasizes mainly via lymphatic vessels, whereas follicular carcinoma spreads mostly hematogenously, there are no data regarding utility of objective quantitative criteria such as lymphatic and general blood vessel density for the differential diagnosis of these lesions.
  • In this study, 35 follicular patterned lesions of thyroid (14 follicular adenomas, 10 follicular carcinomas, and 11 of the follicular variant of papillary thyroid carcinomas) were evaluated immunohistochemically.
  • There were no significant differences in the intra- and/or peritumoral general vessel densities, and peritumoral lymphatic vessel densities among follicular adenoma, follicular carcinoma and the follicular variant of papillary thyroid carcinoma.
  • In contrast, the intratumoral lymphatic vessel density was significantly higher in the follicular variant of papillary thyroid carcinoma than in either follicular adenoma or follicular carcinoma (34.63, 15.04, and 0.11 respectively; P<0.0001).
  • The results of the study show that intratumoral lymphatic vessel density may serve as a useful tool in the differential diagnosis of follicular patterned lesions of thyroid.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymphangiogenesis / physiology. Neovascularization, Pathologic / pathology. Thyroid Neoplasms / blood supply. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenoma / diagnosis. Antibodies, Monoclonal. Antibodies, Monoclonal, Murine-Derived. Antigens, CD31. Carcinoma, Papillary / diagnosis. Diagnosis, Differential. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Modern Pathology (2005) 18, 1424-1431. doi:10.1038/modpathol.3800452; published online 27 May 2005.
  • (PMID = 15920537.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  •  go-up   go-down


32. Sangalli G, Serio G, Zampatti C, Bellotti M, Lomuscio G: Fine needle aspiration cytology of the thyroid: a comparison of 5469 cytological and final histological diagnoses. Cytopathology; 2006 Oct;17(5):245-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of the thyroid: a comparison of 5469 cytological and final histological diagnoses.
  • OBJECTIVE: We evaluated the efficacy of fine needle aspiration cytology (FNAC) of the thyroid in a series of 5469 lesions with histological control and studied the causes of, and the possibility of reducing the limitations of the method.
  • RESULTS: We obtained a complete sensitivity of 93.4%, a positive predictive value of malignancy of 98.6%, and a specificity of 74.9%.
  • At histological control, the cytological diagnosis of Hurthle cell neoplasm corresponded to a significantly higher incidence of malignant neoplasms than the diagnosis of non-Hurthle cell follicular neoplasm (32.1% versus 15.5%).
  • There were 66 false-negative findings, the main cause of diagnostic error (24 cases) being failure to recognize the follicular variant of papillary carcinoma.
  • CONCLUSION: Our study confirmed the great efficacy of thyroid FNAC.
  • Awareness that failure to recognize the follicular variant of papillary carcinoma was the main problem in the interpretation of thyroid FNAC should lead to a decrease of false-negative diagnoses.
  • [MeSH-major] Biopsy, Fine-Needle. Thyroid Nodule / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16961652.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Chowhan AK, Kinnera VS, Yootla M, Reddy MK: Cervical ectopic thymus masquerading as metastatic thyroid papillary carcinoma. Malays J Pathol; 2010 Jun;32(1):65-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical ectopic thymus masquerading as metastatic thyroid papillary carcinoma.
  • We report a 12-year-old female presenting with multinodular thyroid swelling since seven years of age.
  • FNAC revealed adenomatous goitre with suspicious cystic papillary neoplastic foci, for which she underwent total thyroidectomy along with excision of a nodular swelling near the lower pole of the right thyroid lobe which was per-operatively suspected to be a lymph node.
  • Histopathological examination revealed a follicular variant papillary carcinoma of the thyroid with background thyroiditis, and a nodule of ectopic thymic tissue.
  • [MeSH-major] Carcinoma, Papillary / complications. Lymphatic Metastasis / pathology. Thyroid Dysgenesis / complications. Thyroid Dysgenesis / pathology. Thyroid Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20614729.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


34. Carling T, Udelsman R: Follicular neoplasms of the thyroid: what to recommend. Thyroid; 2005 Jun;15(6):583-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular neoplasms of the thyroid: what to recommend.
  • Follicular neoplasms of the thyroid are usually diagnosed following fine-needle aspiration (FNA) biopsy of a dominant thyroid nodule.
  • An FNA diagnosis of a follicular neoplasm represents a heterogeneous group of lesions including benign follicular hyperplasia, follicular adenomas, follicular carcinomas, and the follicular variant of papillary carcinoma.
  • Because the criteria for malignancy in both follicular and Hürthle cell neoplasms requires vascular or capsular invasion seen on permanent histology, the majority of these patients undergo surgical resection.
  • Intraoperative frozen section analysis of follicular neoplasms rarely renders informative information.
  • Postoperative treatment generally includes therapeutic doses of 131I for follicular carcinomas.
  • [MeSH-major] Adenocarcinoma, Follicular / therapy. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029125.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


35. Baloch ZW: Fine-needle aspiration of follicular lesions of the thyroid. Diagnosis and follow-Up. Cytojournal; 2006 Apr 07;3:9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration of follicular lesions of the thyroid. Diagnosis and follow-Up.
  • The differential diagnosis of a follicular lesion/neoplasm in thyroid FNA specimens includes hyperplastic/adenomatoid nodule, follicular adenoma and carcinoma, and follicular variant of papillary thyroid carcinoma.
  • In our laboratory we separate follicular lesions of thyroid into hyperplastic/adenomatoid nodule (HN), follicular neoplasm (FON) and follicular derived neoplasm with focal nuclear features suspicious for papillary thyroid carcinoma (FDN).
  • In the FON category almost half of the malignant cases were papillary carcinoma.
  • According to this study it is important to divide follicular patterned lesions of thyroid into FON and FDN in the cytology specimens due to significantly different risk of malignancy (22% vs. 72%).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 1985 Apr-Jun;1(2):123-32 [3841772.001]
  • [Cites] Henry Ford Hosp Med J. 1982;30(1):17-24 [6896323.001]
  • [Cites] Cytojournal. 2005 Jun 29;2(1):12 [15987502.001]
  • [Cites] Hum Pathol. 1991 Dec;22(12):1195-205 [1748427.001]
  • [Cites] Surgery. 1994 Dec;116(6):1054-60 [7985087.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):552-5 [9195571.001]
  • [Cites] Mayo Clin Proc. 1997 Oct;72(10):913-6 [9379692.001]
  • [Cites] Diagn Cytopathol. 1998 Feb;18(2):87-90 [9484634.001]
  • [Cites] Thyroid. 1998 May;8(5):377-83 [9623727.001]
  • [Cites] Am J Clin Pathol. 1999 Feb;111(2):216-22 [9930143.001]
  • [Cites] Mod Pathol. 1999 Jun;12(6):653-7 [10392643.001]
  • [Cites] Diagn Cytopathol. 2000 Dec;23(6):380-5 [11074641.001]
  • [Cites] Endocr Pract. 2001 Mar-Apr;7(2):79-84 [11421549.001]
  • [Cites] Diagn Cytopathol. 2002 Jan;26(1):41-4 [11782086.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Semin Diagn Pathol. 2002 Nov;19(4):219-26 [12469789.001]
  • [Cites] Ann Pathol. 2003 Feb;23(1):11-20 [12743496.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2761-5 [15102681.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5175-80 [15472223.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):279-87 [15505528.001]
  • (PMID = 16603062.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC1458352
  •  go-up   go-down


36. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK: The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf); 2005 Nov;63(5):588-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
  • BACKGROUND: The BRAF(V600E) mutation, the most common genetic alteration reported in papillary thyroid carcinoma, has been associated with poor prognostic factors.
  • AIM: To determine whether the presence of the BRAF(V600E) mutation is associated with poor prognosis in Korean patients with conventional papillary thyroid microcarcinoma (micro-PTC).
  • PATIENTS AND METHODS: DNA was extracted from paraffin-embedded thyroid tumour specimens taken from 60 patients with conventional micro-PTC, as well as from nine patients with follicular variant papillary carcinoma, six with nodular hyperplasia, four with follicular carcinoma (including one with Hürthle cell carcinoma), four with follicular adenoma (including two with Hürthle cell adenoma) and one each with medullary carcinoma, poorly differentiated carcinoma and anaplastic carcinoma.
  • RESULTS: The BRAF(V600E) mutation was detected in tumour samples from 31 of 60 conventional micro-PTC patients (52%), but was not detected in patients with other types of thyroid tumours.
  • [MeSH-major] Adenoma / genetics. Point Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16268813.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


37. Yu J, Nikiforova MN, Hodak SP, Yim JH, Cai G, Walls A, Nikiforov YE, Seethala RR: Tumor-to-tumor metastases to follicular variant of papillary thyroid carcinoma: histologic, immunohistochemical, and molecular studies of two unusual cases. Endocr Pathol; 2009;20(4):235-42
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-to-tumor metastases to follicular variant of papillary thyroid carcinoma: histologic, immunohistochemical, and molecular studies of two unusual cases.
  • Tumor-to-tumor metastasis in thyroid neoplasms is exceedingly uncommon.
  • Two unusual cases of breast carcinoma and renal cell carcinoma metastatic to follicular variant papillary carcinoma are reported.
  • On histologic sections, the donor tumor cells infiltrated the substance of the recipient tumor and the angiolymphatic channels, but the bulk of metastatic tumor was confined within the thyroid carcinoma.
  • Immunohistochemical stains as well as molecular studies confirmed the origin of both donor tumors, as well as the diagnosis of follicular variant of papillary carcinoma in the recipient tumors.
  • A brief review of literature and discussion of tumor-to-tumor metastasis in thyroid neoplasms is also presented.
  • [MeSH-major] Carcinoma, Papillary, Follicular / pathology. Neoplasm Metastasis / pathology. Neoplasms, Second Primary / pathology. Thyroid Neoplasms / pathology. Thyroid Neoplasms / secondary
  • [MeSH-minor] Biomarkers / analysis. Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Carcinoma, Lobular / secondary. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / secondary. DNA-Binding Proteins / analysis. Female. Galectin 3 / analysis. Humans. Immunohistochemistry. Keratins / analysis. Kidney Neoplasms / pathology. Loss of Heterozygosity. Male. Microsatellite Repeats / genetics. Middle Aged. Neprilysin / analysis. Nuclear Proteins / analysis. Thyroglobulin / analysis. Transcription Factors / analysis. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19707890.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CAM 5.2 antigen; 0 / CITED1 protein, human; 0 / DNA-Binding Proteins; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Nuclear Proteins; 0 / TTF1 protein, human; 0 / Transcription Factors; 0 / Vimentin; 68238-35-7 / Keratins; 9010-34-8 / Thyroglobulin; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


38. Chagas JF, Aquino JL, Pascoal MB, Teixeira AS, Ferro MM, Gambaro MC, Dedivitis RA: Multicentricity in the thyroid differentiated carcinoma. Braz J Otorhinolaryngol; 2009 Jan-Feb;75(1):97-100
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentricity in the thyroid differentiated carcinoma.
  • The treatment of choice for the well differentiated thyroid carcinoma has always been controversial.
  • AIM: to analyze tumor invasion of the thyroid gland's contralateral lobe in cases of differentiated carcinoma, correlating risk/benefit with the complications of a second surgical approach.
  • Patients' ages varied from 17 to 89; the most frequent histopathological pattern was the classical papillary carcinoma (18 cases), followed by follicular carcinoma (6); the follicular variant of the papillary carcinoma (2) and the Hürthle cell carcinoma (1).
  • RESULTS: the contralateral lobe analysis was negative for carcinoma in 16 (76.5%) and positive in the other 5 (23.8%) patients.
  • CONCLUSIONS: total thyroidectomy is important in the treatment of differentiated thyroid carcinomas, because there is a high contralateral spread rate (23.8%).
  • [MeSH-major] Carcinoma / surgery. Thyroid Neoplasms / surgery. Thyroidectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19488567.001).
  • [ISSN] 1808-8694
  • [Journal-full-title] Brazilian journal of otorhinolaryngology
  • [ISO-abbreviation] Braz J Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


39. Denning KM, Smyth PC, Cahill SF, Finn SP, Conlon E, Li J, Flavin RJ, Aherne ST, Guenther SM, Ferlinz A, O'Leary JJ, Sheils OM: A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples. Mod Pathol; 2007 Oct;20(10):1095-102
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples.
  • Follicular variant of papillary thyroid carcinoma is a lesion that frequently causes difficulties from a diagnostic perspective in the laboratory.
  • The purpose of this study was to interrogate a cohort of archival thyroid lesions using gene expression analysis of a panel of markers proposed to have utility as adjunctive markers in the diagnosis of thyroid neoplasia and follicular variant of papillary thyroid carcinoma in particular.
  • HLA-DMA, HLA-DQB1, MT1X, CSNK1G2 and RAB23 were found to be differentially expressed (P<0.05) when comparing follicular adenoma and follicular variant of papillary thyroid carcinoma.
  • Comparison of follicular adenoma and follicular thyroid carcinoma groups showed significant differential expression for MT1K, MT1X and RAB23 (P<0.05).
  • Comparison of the papillary thyroid carcinoma group (classic and follicular variants) and the follicular adenoma group showed differential expression for CSNK1G2, HLA-DQB1, MT1X and RAB23 (P<0.05).
  • Finally, KRAS2 was found to be differentially expressed (P<0.05) when comparing the papillary thyroid carcinoma and follicular thyroid carcinoma groups.
  • This panel of molecular targets discriminates between follicular adenoma, papillary thyroid carcinoma, follicular variant of papillary thyroid carcinoma and follicular thyroid carcinoma by their expression repertoires.
  • It may have utility for broader use in the setting of fine-needle aspiration cytology and could improve the definitive diagnosis of certain categories of thyroid malignancy.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Papillary / genetics. Carcinoma, Papillary, Follicular / genetics. Gene Expression. Reverse Transcriptase Polymerase Chain Reaction / methods. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660800.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


40. Laco J, Ryska A: [The use of immunohistochemistry in the differential diagnosis of thyroid gland tumors with follicular growth pattern]. Cesk Patol; 2006 Jul;42(3):120-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The use of immunohistochemistry in the differential diagnosis of thyroid gland tumors with follicular growth pattern].
  • The aim of the study was to evaluate the expression of galectin-3 (gal3), cytokeratin 19 (CK19), neural cell adhesion molecule (NCAM), and E-cadherin (Ecad) in thyroid gland tumors with follicular growth pattern with particular focus on their use in differential diagnosis.
  • A series of 139 cases - 87 follicular adenomas (FAs), 26 follicular carcinomas (FCs), and 26 cases of the follicular variant of papillary carcinoma (FVPC) was studied.
  • [MeSH-major] Biomarkers, Tumor / analysis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / chemistry. Adenoma / diagnosis. Adolescent. Adult. Aged. Aged, 80 and over. Cadherins / analysis. Carcinoma, Papillary / chemistry. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary, Follicular / chemistry. Carcinoma, Papillary, Follicular / diagnosis. Diagnosis, Differential. Female. Galectin 3 / analysis. Humans. Immunohistochemistry. Keratins / analysis. Male. Middle Aged. Neural Cell Adhesion Molecule L1 / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955558.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Galectin 3; 0 / Neural Cell Adhesion Molecule L1; 68238-35-7 / Keratins
  •  go-up   go-down


41. Falvo L, Marzullo A, Palermo S, Biancafarina A, De Stefano M, Vanni B, Sorrenti S, Catania A: The sentinel lymph node in papillary cancer of the thyroid including histological subtype. Ann Ital Chir; 2006 Jan-Feb;77(1):13-8; discussion 18
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The sentinel lymph node in papillary cancer of the thyroid including histological subtype.
  • MATERIALS AND METHODS: At the Surgical Science Department of La Sapienza University of Rome The Authors studied from January 2003 to June 2004 18 patients with papillary carcinoma of the thyroid, who presented no clinical evidence of lymph node metastasis; they performed a total thyroidectomy in all cases, removing and histologically examining all lymph nodes of the upper anterior mediastinum.
  • RESULTS: The method was positive in 10 patients: 2 pure papillary carcinomas, 1 papillary carcinoma with poorly differentiated areas, 1 tall cell papillary carcinoma, 5 sclerosing carcinoma and 1 follicular variant papillary carcinoma; and negative in 8:5 pure papillary carcinomas, 2 sclerosing carcinoma and 1 case of follicular variant papillary carcinoma.
  • The Authors can propose two main applications: select for dissection only patients with a positive sentinel node and reduce the number of cases to be subjected to postoperative treatment with iodine ablation, in patients with "low risk" thyroid tumours and negative sentinel nodes.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Lymph Nodes / pathology. Lymph Nodes / surgery. Sentinel Lymph Node Biopsy. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910354.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


42. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE: Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol; 2006 Feb;30(2):216-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas.
  • Papillary carcinoma is the most common type of thyroid malignancy.
  • In this study, we analyze the relationship between these alterations and the microscopic features of papillary carcinomas, their clinical features, and prognostic characteristics.
  • Ninety-seven papillary carcinomas were studied; in all cases, frozen tissue was available for nucleic acid extraction.
  • Morphologic features were evaluated in detail in 61 cases and 6 characteristic nuclear features and 3 additional microscopic features were assessed quantitatively.
  • At least 4 nuclear features were found in each tumor, with nuclear pseudoinclusions being the least frequent finding in all mutation groups.
  • BRAF mutations were associated with older patient age, typical papillary appearance or the tall cell variant, a higher rate of extrathyroidal extension, and more advanced tumor stage at presentation.
  • RET/PTC rearrangements presented at younger age and had predominantly typical papillary histology, frequent psammoma bodies, and a high rate of lymph node metastases.
  • Tumors with RAS mutations were exclusively the follicular variant of papillary carcinoma and correlated with significantly less prominent nuclear features and low rate of lymph node metastases.
  • These findings demonstrate that BRAF, RET/PTC, and RAS mutations are associated with distinct microscopic, clinical, and biologic features of thyroid papillary carcinomas.
  • [MeSH-major] Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434896.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA88041
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


43. Pang T, Ihre-Lundgren C, Gill A, McMullen T, Sywak M, Sidhu S, Delbridge L: Correlation between indeterminate aspiration cytology and final histopathology of thyroid neoplasms. Surgery; 2010 Sep;148(3):532-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between indeterminate aspiration cytology and final histopathology of thyroid neoplasms.
  • BACKGROUND: Of all thyroid nodules assessed by fine needle aspiration cytology (FNAC), 10-20% are classified as indeterminate/atypical.
  • Traditionally, this group is considered to primarily represent follicular neoplasia.
  • We hypothesize that papillary carcinoma accounts for a significant proportion of lesions classified as "atypical" on FNAC.
  • METHODS: This retrospective study includes 228 patients who had an atypical FNAC result and who were subsequently found to have a malignancy on histologic examination of the excised thyroid lesion.
  • Patients with papillary microcarcinomas, defined as lesions less than 10-mm diameter, were excluded.
  • Prevalence of papillary carcinoma was not statistically significant (33/76 vs 34/76 vs 46/76; P = .0636), but showed a statistical significant trend to increase over time (P = .0349).
  • Prevalence of follicular variant papillary carcinoma was also found to be significantly different between the groups (7/76 vs 12/76 vs 19/76; P = .0320; P = .0349).
  • CONCLUSION: Papillary carcinoma accounted for most histopathologically confirmed cancers that had an atypical cytology.
  • Papillary cancer in this group of patients trended up, probably due to a significant increase in the diagnosis of follicular variant of papillary cancer.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Biopsy, Needle / methods. Carcinoma, Papillary / surgery. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery. Thyroidectomy / methods
  • [MeSH-minor] Adolescent. Adult. Chi-Square Distribution. Child. Child, Preschool. Female. Genetic Variation. Goiter / pathology. Humans. Male. Middle Aged. Patient Selection. Thyroid Nodule / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20236675.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Berni Canani F, Dall'Olio D, Chiarini V, Casadei GP, Papini E: Papillary carcinoma of a thyroglossal duct cyst in a patient with thyroid hemiagenesis: effectiveness of conservative surgical treatment. Endocr Pract; 2008 May-Jun;14(4):465-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary carcinoma of a thyroglossal duct cyst in a patient with thyroid hemiagenesis: effectiveness of conservative surgical treatment.
  • OBJECTIVE: To describe a case of thyroglossal duct cyst carcinoma that arose in a patient with right thyroid lobe hemiagenesis.
  • The patient's preoperative workup included ultrasonography of the neck and head and neck T1- and T2-weighted magnetic resonance imaging, which showed right hemithyroid agenesis and a cystic lesion in the median region of the neck below the hyoid bone.
  • Findings from chest x-rays and thyroid function tests were normal.
  • Histologic findings showed a 2.5-cm thyroglossal duct cyst with a 0.6-cm focus of follicular variant of papillary carcinoma with invasion of the cyst wall.
  • Total thyroidectomy was not performed because of the absence of tumoral invasion of the parenchyma around the thyroglossal duct cyst and because the patient was at low risk for aggressive disease.
  • Presently, the patient is symptom-free after 4 years of follow-up and has no evidence of disease.
  • CONCLUSION: Incidentally discovered, well-differentiated thyroid cancer that is confined to a thyroglossal duct cyst in a patient at low risk for aggressive disease can be adequately treated by a modified Sistrunk procedure that includes the median portion of the hyoid bone.
  • [MeSH-major] Carcinoma, Papillary / surgery. Thyroglossal Cyst / surgery. Thyroid Dysgenesis / surgery. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Thyroid Gland / abnormalities. Thyroid Gland / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18558601.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Tabriz HM, Adabi Kh, Lashkari A, Heshmat R, Haghpanah V, Larijani B, Tavangar SM: Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm. Pathol Res Pract; 2009;205(2):83-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
  • INTRODUCTION: We aimed at assessing the significance of nm23 gene expression in papillary and follicular carcinomas, the two most common differentiated thyroid carcinomas.
  • MATERIALS AND METHODS: During a cross-sectional study, 173 paraffin blocks, including 131 papillary thyroid carcinomas, 12 follicular carcinomas and 30 follicular adenomas were stained with nm23 marker by immunohistochemistry method.
  • RESULTS: nm23 was positive in 40% of the follicular adenoma, 67.2% of the papillary carcinoma and 66.7% of the follicular carcinoma. p value was more than 0.05 in the assessment of the relationship between nm23 and all of the above-mentioned parameters in differentiated thyroid carcinomas. nm23 expression did not significantly differentiate between follicular adenoma and carcinoma.
  • Also, nm23 cannot be considered as a useful marker for the evaluation of invasion in differentiated thyroid carcinomas or in distinctions between follicular adenoma and carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Papillary / metabolism. Adenoma / metabolism. NM23 Nucleoside Diphosphate Kinases / biosynthesis. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18996649.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NM23 Nucleoside Diphosphate Kinases; EC 2.7.4.6 / NME1 protein, human
  •  go-up   go-down


46. Hagag P, Hod N, Kummer E, Cohenpour M, Horne T, Weiss M: Follicular variant of papillary thyroid carcinoma: clinical-pathological characterization and long-term follow-up. Cancer J; 2006 Jul-Aug;12(4):275-82
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular variant of papillary thyroid carcinoma: clinical-pathological characterization and long-term follow-up.
  • PURPOSE: Questions arise concerning the behavior and prognosis of the follicular variant of papillary thyroid carcinoma.
  • PATIENTS AND METHODS: Between 1990 and 2003, 92 patients with follicular variant of papillary carcinoma (group A) were enrolled in a long-term study and compared with control groups of follicular thyroid carcinoma (group B, 40 cases) and pure papillary thyroid carcinoma (group C, 99 subjects).
  • The rate of metastasis tumors was higher in group A than in group C and was comparable in groups A and B.
  • Persistent stable lesions and progressive disease rates in groups B, A, and C were 2.5% and 2.5%, 15% and 8%, and 0% and 2%, respectively.
  • DISCUSSION: Follicular variant of papillary thyroid carcinoma may be more aggressive than previously considered and should be clearly distinguished from the two other forms of well-differentiated thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary, Follicular. Thyroid Neoplasms
  • [MeSH-minor] Adult. Cell Differentiation. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer J. 2006 Jul-Aug;12(4):250-2 [16925968.001]
  • (PMID = 16925971.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Yang CS, Zhang Q, Guo ZM, Zeng ZY, Lai FY: [Childhood thyroid carcinoma: clinical analyses of 22 cases]. Ai Zheng; 2008 Mar;27(3):311-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Childhood thyroid carcinoma: clinical analyses of 22 cases].
  • BACKGROUND & OBJECTIVE: Thyroid carcinoma is rarely occurred in children.
  • Clinicopathologic characteristics, therapy and prognosis of childhood thyroid carcinoma patients are different from those of adult patients, and the treatment of this disease is controversial.
  • This study was to explore the clinicopathologic characteristics, diagnosis and therapy of thyroid carcinoma in children.
  • METHODS: Clinical data of 22 children under the age of 14, diagnosed as thyroid carcinoma between Jan.
  • Of the 22 patients, 8 (36.4%) had papillary carcinoma, 8 (36.4%) had follicular carcinoma, 5(22.7%) had mixed papillary-follicular carcinoma, and 1 (4.5%) had medullary carcinoma.
  • CONCLUSIONS: Childhood thyroid carcinomas are mostly differentiated carcinomas, with high frequency of cervical lymph node metastases.
  • The optimal treatment for thyroid carcinoma in children may improve the quality of life and decrease the incidence of complications.
  • [MeSH-major] Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334124.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


48. Dănilă R, Andriescu L, Dăscălescu C, Lefter LP, Popovici R, Găluşcă B, Vulpoi C, Ungureanu C, Mogoş V, Dragomir C: [Differentiated thyroid cancer--peculiar morphological and clinical forms]. Rev Med Chir Soc Med Nat Iasi; 2005 Oct-Dec;109(4):746-52
MedlinePlus Health Information. consumer health - Thyroid Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differentiated thyroid cancer--peculiar morphological and clinical forms].
  • The most common clinical presentation of differentiated thyroid cancer (DTC), consisting of papillary and follicular adenocarcinoma (with their histological variants), is the solitary thyroid nodule.
  • A review of the literature is performed in order to describe particular forms of DTC, in terms of incidence, diagnosis and treatment: occult carcinoma, carcinoma on aberrant thyroid tissue, "functional" thyroid carcinoma and familial non-medullary carcinoma.
  • A particular interest is shown to the coexistence of malignancy with benign thyroid diseases, such as goiter, hyperthyroidism and Hashimoto's thyroiditis, as well as parathyroid adenoma.
  • In conclusion, the authors emphasize that the association of carcinoma with benign thyroid conditions is not rare and it substantiate an aggressive approach in regard to diagnosis and treatment, increasing the indication for surgery and, moreover, for total thyroidectomy.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Papillary / pathology. Thyroid Diseases / complications. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16610171.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 46
  •  go-up   go-down


49. Wang HM, Huang YW, Huang JS, Wang CH, Kok VC, Hung CM, Chen HM, Tzen CY: Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma. Ann Surg Oncol; 2007 Oct;14(10):3011-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
  • BACKGROUND: Anaplastic thyroid carcinoma (ATC), a rare and highly malignant tumor, has long been thought to arise from well-differentiated carcinoma (WDC) such as follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma (PTC).
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Papillary / genetics. Biomarkers, Tumor / genetics. Carcinoma / genetics. Cell Transformation, Neoplastic / genetics. Neoplasms, Multiple Primary / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Base Sequence / genetics. Cell Line, Tumor. Codon / genetics. DNA Mutational Analysis. Exons / genetics. Female. Gene Expression Regulation, Neoplastic / physiology. Humans. Male. Middle Aged. Phosphatidylinositol 3-Kinases / genetics. Polymerase Chain Reaction. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins p21(ras) / genetics. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA. Thyroid Gland / pathology. Thyroid Gland / surgery. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638058.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Codon; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


50. Chaabouni AM, Intidhar Labidi S, Kraiem T, Gammoudi A, Ladgham A, Ben Slimane F: [Papillary-follicular carcinoma arising in a lingual thyroid]. Ann Otolaryngol Chir Cervicofac; 2006 Sep;123(4):199-202
MedlinePlus Health Information. consumer health - Tongue Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Papillary-follicular carcinoma arising in a lingual thyroid].
  • [Transliterated title] Carcinome vesiculo-papillaire sur thyroïde linguale.
  • OBJECTIVES: The management of diagnosis, treatment and outcome of malignant neoplasm arising in a lingual thyroid.
  • MATERIAL AND METHODS: We report a case of papillary-follicular carcinoma arising in a lingual thyroid.
  • RESULTS: Lingual carcinoma causes dysphagia and pain due to oropharyngeal obstruction.
  • Therefore, the eutopic thyroid was present, in pretracheal position, without neoplastic proliferation.
  • CONCLUSIONS: Carcinoma arising in lingual thyroid is an extreme rare entity.
  • [MeSH-major] Carcinoma, Papillary, Follicular. Choristoma. Thyroid Gland. Thyroid Neoplasms. Tongue Diseases / complications. Tongue Neoplasms

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17088708.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


51. Nagano J, Mabuchi K, Yoshimoto Y, Hayashi Y, Tsuda N, Land C, Kodama K: A case-control study in Hiroshima and Nagasaki examining non-radiation risk factors for thyroid cancer. J Epidemiol; 2007 May;17(3):76-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case-control study in Hiroshima and Nagasaki examining non-radiation risk factors for thyroid cancer.
  • BACKGROUND: Because little is known about the etiology of thyroid cancer in Japan, we conducted a case-control study of thyroid cancer and lifestyle and other risk factors.
  • METHODS: Thyroid cancer cases reported to the Hiroshima and Nagasaki tumor registries during 1970-1986 were histologically reviewed by pathologists.
  • For each of 362 cases with papillary or follicular adenocarcinoma diagnosed at <75 years of age, one control without cancer matched on city, sex, year of birth, and atomic-bomb radiation exposure was selected from the Life Span Study cohort or the offspring cohort.
  • RESULTS: Analysis using conditional logistic regression showed history of goiter or thyroid nodule and family history of cancer to be significantly associated with an increased odds ratio for thyroid cancer.
  • Radiation exposure did not significantly modify the associations between these factors and thyroid cancer risk.
  • CONCLUSION: History of goiter/nodule and family history of cancer were risk factors for thyroid cancer.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545694.001).
  • [ISSN] 0917-5040
  • [Journal-full-title] Journal of epidemiology
  • [ISO-abbreviation] J Epidemiol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radioactive Fallout
  •  go-up   go-down


52. Sadow PM, Hunt JL: Mixed Medullary-follicular-derived carcinomas of the thyroid gland. Adv Anat Pathol; 2010 Jul;17(4):282-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed Medullary-follicular-derived carcinomas of the thyroid gland.
  • Tumors of the thyroid are subclassified based on the cell of origin and commonly include follicular-derived tumors and C-cell-derived tumors.
  • The most common follicular-derived tumors are papillary carcinoma and follicular carcinoma, whereas the malignant C-cell-derived tumor is medullary thyroid carcinoma.
  • Rare cases in the literature describe patients who have follicular-derived and C-cell-derived tumors in the same thyroid gland.
  • The mixture may be at an interface, as in collision tumors, or can be throughout the entire lesion, as in true mixed medullary-follicular-derived carcinomas.
  • The clinical, histologic, and molecular features of these mixed tumors and the classification guidelines are reviewed.
  • [MeSH-major] Carcinoma, Medullary / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Papillary, Follicular / complications. Carcinoma, Papillary, Follicular / epidemiology. Carcinoma, Papillary, Follicular / pathology. Humans

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20574174.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


53. Yamane GK: Cancer incidence in the U.S. Air Force: 1989-2002. Aviat Space Environ Med; 2006 Aug;77(8):789-94
MedlinePlus Health Information. consumer health - Veterans and Military Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among men, the 10 most frequent cancers (77.6% of total) were, in descending order: melanoma; testicular CA; prostate CA; non-Hodgkin lymphoma; follicular/papillary thyroid CA; Hodgkin's Disease; colorectal CA; brain neuroepithelial CA; and (tied) bladder CA and oral squamous cell CA.
  • Among women, the 10 most frequent cancers (88.1% of total) were, in descending order: breast CA; cervical CA; follicular/papillary thyroid CA; melanoma; Hodgkin's Disease; colorectal CA;.
  • (tied) non-Hodgkin lymphoma and ovarian epithelial CA; vulvar CA; and (tied) brain neuroepithelial CA and oral squamous cell CA.
  • Compared with the U.S. population, cancer type-specific SIRs were significantly increased for cervical CA, prostate CA, and vulvar CA (range, 1.44-3.54).
  • SIRs were significantly decreased for bladder CA (men), brain neuroepithelial CA, colorectal CA (men), Hodgkin's Disease (men), non-Hodgkin lymphoma, oral squamous cell CA (men), and testicular CA (range, 0.31-0.68).

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909871.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Tsuge K, Takeda H, Kawada S, Maeda K, Yamakawa M: Characterization of dendritic cells in differentiated thyroid cancer. J Pathol; 2005 Apr;205(5):565-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of dendritic cells in differentiated thyroid cancer.
  • In this study, the types and localization pattern of dendritic cells (DCs), the expression of chemokines on carcinoma cells and of the relevant receptors on DCs, and the adhesion molecules expressed on vascular endothelial cells and DCs were examined in thyroid carcinomas.
  • Papillary carcinoma had a higher frequency of CD1a(+) immature DCs than other thyroid tumours.
  • Macrophage inflammatory protein (MIP)-3 alpha was expressed strongly on the majority of papillary carcinoma cells and weakly on a minority of follicular carcinoma cells.
  • DCs positive for chemokine receptor-6 (CCR-6) were densely accumulated in papillary carcinoma.
  • DC-SIGN(+) DCs were accumulated in papillary carcinoma but rarely in follicular carcinoma.
  • A binding assay for DC-SIGN-mediated adhesion of isolated DCs revealed significant inhibition of DC adhesion to papillary carcinoma tissues by neutralizing antibodies against intercellular adhesion molecule-2 or DC-SIGN.
  • These results clearly indicated marked differences between papillary carcinoma and follicular carcinoma in the accumulation of immature DCs, in MIP-3 alpha expression on carcinoma cells, and in the frequency of CCR-6(+) DCs and DC-SIGN(+) DCs.
  • [MeSH-major] Adenocarcinoma, Follicular / immunology. Carcinoma, Papillary / immunology. Dendritic Cells / immunology. Neoplasm Proteins / metabolism. Thyroid Neoplasms / immunology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714595.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CCR6 protein, human; 0 / Cell Adhesion Molecules; 0 / Chemokines; 0 / HLA-DR Antigens; 0 / ICAM2 protein, human; 0 / Neoplasm Proteins; 0 / Receptors, CCR6; 0 / Receptors, Chemokine
  •  go-up   go-down


55. Sergieva S, Hadjieva T, Doldurova M, Stefanova S, Dudov A: Nuclear medicine approaches in the monitoring of thyroid cancer patients. J BUON; 2006 Oct-Dec;11(4):511-8
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear medicine approaches in the monitoring of thyroid cancer patients.
  • PURPOSE: To evaluate the role of some nuclear medicine approaches such as (99m)Tc-MIBI scan and (131)I whole-body scintigraphy (WBS) in the monitoring of patients with differentiated thyroid cancer (DTC).
  • PATIENTS AND METHODS: 95 patients (69F/26M) aged 17-74 years (mean 44.2) with DTC (56 cases with papillary, 20 with follicular and 19 with papillary-follicular carcinoma) were assessed.
  • All of them had undergone total or near-total thyroidectomy and received radioiodine treatment for ablation of post-surgical residual thyroid tissue.
  • RESULTS: (131)I scan was positive in 63 patients showing thyroid remnants in 31 cases, lymph node metastases in 24 cases (17 to the neck, 7 to the neck/mediastinum), pulmonary metastases in 6 cases, bone and brain lesions in 2 cases.
  • These false negative results were observed predominantly in cases with less differentiated metastatic disease, especially after several courses of high-dose (131)I therapy. (99m)Tc-MIBI scan revealed the presence of lymph node and/or lung metastases (non-functioning metastases) in 14 of them, false negative results were obtained in 2 cases, and one false positive in 1 case.
  • Serum Tg was increased in all patients with local lymph node and distant metastases, visualized by (131)I or by (99m)Tc-MIBI, but also in 18 patients with thyroid remnants only.
  • [MeSH-major] Patient Care Planning. Radiopharmaceuticals. Technetium Tc 99m Sestamibi. Thyroid Neoplasms / radionuclide imaging
  • [MeSH-minor] Adenocarcinoma, Follicular / radionuclide imaging. Adenocarcinoma, Follicular / therapy. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / radionuclide imaging. Carcinoma, Papillary / therapy. Female. Follow-Up Studies. Humans. Iodine Radioisotopes / therapeutic use. Lymphatic Metastasis / diagnosis. Magnetic Resonance Imaging. Male. Middle Aged. Neck / ultrasonography. Sensitivity and Specificity. Thyroglobulin / blood. Thyroidectomy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309186.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 9010-34-8 / Thyroglobulin; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


56. Kakudo K, Bai Y, Katayama S, Hirokawa M, Ito Y, Miyauchi A, Kuma K: Classification of follicular cell tumors of the thyroid gland: analysis involving Japanese patients from one institute. Pathol Int; 2009 Jun;59(6):359-67
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of follicular cell tumors of the thyroid gland: analysis involving Japanese patients from one institute.
  • Prognostic analyses of thyroid carcinomas of follicular cell origin were carried out on patients treated at Kuma Hospital, Kobe, Japan.
  • Major histological types of papillary carcinoma, follicular carcinoma and poorly differentiated carcinoma were combined into one single entity of follicular cell adenocarcinoma because (i) they have the same cell origin (follicular cell);.
  • (ii) clear-cut separation of papillary and follicular carcinoma is not always possible, and 10 year cause-specific survival was essentially similar when the patients were treated curatively; and (iii) poorly differentiated carcinoma usually has a background of either papillary or follicular carcinoma.
  • This adenocarcinoma together with undifferentiated carcinoma was stratified into four prognostic groups using pure morphological criteria of the degree of cellular differentiation and histological grade.
  • They are termed well-differentiated adenocarcinoma, moderately differentiated adenocarcinoma, poorly differentiated carcinoma and undifferentiated carcinoma of the thyroid.
  • The 10 year disease-free survival rates were 86.3-93.1%, 65.4-78.7%, and 43.0-53.8%, and 0%, respectively.
  • [MeSH-major] Adenocarcinoma, Follicular / classification. Thyroid Neoplasms / classification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19490465.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Number-of-references] 67
  •  go-up   go-down


57. Takano T, Ito Y, Hirokawa M, Yoshida H, Miyauchi A: BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer; 2007 May 21;96(10):1549-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas.
  • Frequency of a BRAF V600E mutation in anaplastic thyroid carcinoma, which is thought to be derived mainly from papillary carcinoma by multi-step carcinogenesis, is much lower than that in papillary carcinomas.
  • To clarify this phenomenon, we analysed BRAF V600E mutation in 20 cases of anaplastic carcinoma and 13 accompanying differentiated carcinomas.
  • Among twenty cases of anaplastic carcinomas, nine and four accompanied papillary and follicular carcinomas, respectively.
  • BRAF V600E mutation was found in three of nine (33.3%), none of four and one of seven (14.3%) anaplastic carcinomas with papillary carcinoma, follicular carcinoma and without differentiated components, respectively.
  • All three papillary carcinomas accompanied by anaplastic carcinoma with a BRAF V600E mutation were also shown to have a BRAF V600E mutation.
  • In summary, BRAF V600E mutation was occasionally observed in anaplastic carcinomas with papillary carcinoma, and the low frequency of BRAF V600E mutation in anaplastic carcinoma was thought to be due to the low frequency of anaplastic carcinomas with papillary carcinoma.
  • These findings raise a question about the classical model of anaplastic transformation and suggest some roles of thyroid cancer stem cells in the generation of anaplastic carcinoma.
  • [MeSH-major] Carcinoma / genetics. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. DNA Mutational Analysis. Disease Progression. Female. Gene Frequency. Glutamic Acid / genetics. Humans. Male. Middle Aged. Models, Biological. Mutation, Missense. Valine / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. L-Valine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] Semin Cancer Biol. 2007 Jun;17(3):233-40 [16569505.001]
  • [Cites] Pathology. 2002 Feb;34(1):94-7 [11902457.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4393-7 [12970315.001]
  • [Cites] Oncogene. 2003 Sep 25;22(41):6455-7 [14508525.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1365-8 [15001635.001]
  • [Cites] Virchows Arch. 2004 Jun;444(6):572-6 [15095090.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1359-63 [15195111.001]
  • [Cites] Endocrinol Metab Clin North Am. 1990 Sep;19(3):545-76 [2261906.001]
  • [Cites] Endocr Rev. 1994 Apr;15(2):202-32 [8026388.001]
  • [Cites] World J Surg. 1996 Sep;20(7):848-53; discussion 853 [8678961.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):287-94 [9516913.001]
  • [Cites] Endocr J. 2004 Dec;51(6):509-15 [15644567.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2261-8 [15880523.001]
  • [Cites] Thyroid. 2005 May;15(5):432-8 [15929664.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):245-62 [15947100.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9 [16174717.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • (PMID = 17453004.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 3KX376GY7L / Glutamic Acid; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; HG18B9YRS7 / Valine
  • [Other-IDs] NLM/ PMC2359941
  •  go-up   go-down


58. Moncayo R, Kroiss A, Oberwinkler M, Karakolcu F, Starzinger M, Kapelari K, Talasz H, Moncayo H: The role of selenium, vitamin C, and zinc in benign thyroid diseases and of selenium in malignant thyroid diseases: Low selenium levels are found in subacute and silent thyroiditis and in papillary and follicular carcinoma. BMC Endocr Disord; 2008;8:2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of selenium, vitamin C, and zinc in benign thyroid diseases and of selenium in malignant thyroid diseases: Low selenium levels are found in subacute and silent thyroiditis and in papillary and follicular carcinoma.
  • BACKGROUND: Thyroid physiology is closely related to oxidative changes.
  • The aim of this controlled study was to evaluate the levels of nutritional anti-oxidants such as vitamin C, zinc (Zn) and selenium (Se), and to investigate any association of them with parameters of thyroid function and pathology including benign and malignant thyroid diseases.
  • METHODS: This controlled evaluation of Se included a total of 1401 subjects (1186 adults and 215 children) distributed as follows: control group (n = 687), benign thyroid disease (85 children and 465 adults); malignant thyroid disease (2 children and 79 adults).
  • Clinical evaluation of patients with benign thyroid disease included sonography, scintigraphy, as well as the determination of fT3, fT4, TSH, thyroid antibodies levels, Se, Zn, and vitamin C.
  • Besides the routine oncological parameters (TG, TSH, fT4, ultrasound) Se was also determined in the cases of malignant disease.
  • The Ho stated that there should be no differences in the levels of antioxidants between controls and thyroid disease patients.
  • RESULTS: Among the thyroid disease patients neither vitamin C, nor Zn nor Se correlated with any of the following parameters: age, sex, BMI, body weight, thyroid scintigraphy, ultrasound pattern, thyroid function, or thyroid antibodies.
  • The proportion of patients with benign thyroid diseases having analyte concentrations below external reference cut off levels were 8.7% of cases for vitamin C; 7.8% for Zn, and 20.3% for Se.
  • Se levels were significantly decreased in cases of sub-acute and silent thyroiditis (66.4 +/- 23.1 microg/l and 59.3 +/- 20.1 microg/l, respectively) as well as in follicular and papillary thyroid carcinoma.
  • Patients with benign or malignant thyroid diseases can present low Se levels as compared to controls.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2002 Mar;48(3):555-60 [11861447.001]
  • [Cites] J Trace Elem Med Biol. 2002;16(1):1-8 [11878747.001]
  • [Cites] Thyroid. 2003 Jul;13(7):643-8 [12964969.001]
  • [Cites] J Gerontol. 1956 Jul;11(3):298-300 [13332224.001]
  • [Cites] AIDS Res Hum Retroviruses. 1992 Sep;8(9):1547 [1333778.001]
  • [Cites] Br J Psychiatry. 1992 Oct;161:535-41 [1393342.001]
  • [Cites] Clin Chim Acta. 1992 Oct 30;211(3):189-90 [1458613.001]
  • [Cites] Biomed Pharmacother. 2003 Nov;57(9):399-411 [14652165.001]
  • [Cites] Clin Chim Acta. 2004 Apr;342(1-2):187-92 [15026280.001]
  • [Cites] Endocr Rev. 2000 Aug;21(4):412-43 [10950159.001]
  • [Cites] Lancet. 2000 Jul 15;356(9225):233-41 [10963212.001]
  • [Cites] Nature. 2000 Nov 9;408(6809):239-47 [11089981.001]
  • [Cites] J Physiol Biochem. 2000 Sep;56(3):217-22 [11198158.001]
  • [Cites] Ann N Y Acad Sci. 2000;917:906-12 [11268420.001]
  • [Cites] Free Radic Biol Med. 2001 Mar 15;30(6):665-70 [11295364.001]
  • [Cites] J Autoimmun. 2001 Jun;16(4):457-62 [11437494.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):841-9 [15191356.001]
  • [Cites] Acta Med Austriaca. 1992;19 Suppl 1:62-5 [1519457.001]
  • [Cites] Trends Microbiol. 2004 Sep;12(9):417-23 [15337163.001]
  • [Cites] Digestion. 2004;70(3):139-45 [15467295.001]
  • [Cites] Thyroid. 2004 Dec;14(12):1047-55 [15650357.001]
  • [Cites] J Endocrinol. 2005 Mar;184(3):455-65 [15749805.001]
  • [Cites] Am J Clin Nutr. 2005 Apr;81(4):829-34 [15817859.001]
  • [Cites] Atherosclerosis. 2005 Aug;181(2):215-24 [15893757.001]
  • [Cites] Neuroscience. 2005;133(3):715-27 [15908128.001]
  • [Cites] Clin Nutr. 2005 Aug;24(4):530-1 [15998552.001]
  • [Cites] Br J Nutr. 2005 Jul;94(1):125-32 [16115341.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1131-5 [16133381.001]
  • [Cites] Endocr Rev. 2005 Dec;26(7):944-84 [16174820.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1234-41 [16227999.001]
  • [Cites] Am J Epidemiol. 2006 Jan 1;163(1):18-26 [16306311.001]
  • [Cites] Br J Nutr. 2005 Dec;94(6):962-8 [16351774.001]
  • [Cites] J Nutr. 2006 Jan;136(1):172-6 [16365078.001]
  • [Cites] Thyroid. 2005 Oct;15(10):1204-5 [16425442.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2126-32 [16537677.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):804-10 [16614127.001]
  • [Cites] Horm Res. 2006;66(1):21-6 [16685132.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3337-43 [16804039.001]
  • [Cites] J Endocrinol. 2006 Jul;190(1):151-6 [16837619.001]
  • [Cites] J Am Coll Cardiol. 2006 Aug 15;48(4):677-85 [16904534.001]
  • [Cites] Magnes Res. 2006 Jun;19(2):102-6 [16955721.001]
  • [Cites] Pol Merkur Lekarski. 2006 Jun;20(120):672-7 [17007265.001]
  • [Cites] Acta Histochem. 2006;108(6):431-9 [17046053.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Apr;92(4):1263-8 [17284630.001]
  • [Cites] Eur J Clin Nutr. 2008 Jan;62(1):127-37 [17311055.001]
  • [Cites] BMC Musculoskelet Disord. 2007;8:17 [17319961.001]
  • [Cites] JAMA. 2007 Feb 28;297(8):842-57 [17327526.001]
  • [Cites] Nutr J. 2007;6:7 [17386096.001]
  • [Cites] Analyst. 1995 Mar;120(3):833-6 [7741236.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Mar;42(3):303-8 [7758236.001]
  • [Cites] J Med Virol. 1994 Jun;43(2):166-70 [8083665.001]
  • [Cites] Can J Physiol Pharmacol. 1993 Sep;71(9):721-4 [8313237.001]
  • [Cites] Br J Nutr. 1993 Mar;69(2):577-88 [8490010.001]
  • [Cites] J Nutr. 1996 Jan;126(1):138-45 [8558294.001]
  • [Cites] J Radiat Res. 1995 Sep;36(3):196-202 [8558496.001]
  • [Cites] Thyroid. 1995 Oct;5(5):379-82 [8563476.001]
  • [Cites] Eur J Clin Nutr. 1996 Mar;50(3):192-4 [8654334.001]
  • [Cites] Nutrition. 1995 Sep-Oct;11(5 Suppl):573-5 [8748225.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 1997 Jan 24;688(2):345-9 [9061474.001]
  • [Cites] J Am Coll Nutr. 1997 Apr;16(2):175-80 [9100219.001]
  • [Cites] Endocrinology. 1997 Jul;138(7):2871-8 [9202230.001]
  • [Cites] J Am Coll Nutr. 1997 Aug;16(4):357-65 [9263186.001]
  • [Cites] J Vet Med Sci. 1997 Nov;59(11):1017-21 [9409517.001]
  • [Cites] Int J Vitam Nutr Res. 1998;68(1):3-20 [9503043.001]
  • [Cites] Eur J Clin Nutr. 1998 May;52(5):363-7 [9630388.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Jul;55(1):15-9 [11453947.001]
  • [Cites] Atherosclerosis. 2001 Sep;158(1):1-12 [11500168.001]
  • [Cites] Lancet. 2001 Feb 24;357(9256):619-24 [11558500.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2001;109(1):13-7 [11573132.001]
  • [Cites] Clin Chim Acta. 2002 Feb;316(1-2):137-46 [11750284.001]
  • [Cites] J Leukoc Biol. 2002 Jan;71(1):16-32 [11781377.001]
  • [Cites] Exp Biol Med (Maywood). 2002 Feb;227(2):141-6 [11815678.001]
  • [Cites] Biol Trace Elem Res. 2001 Winter;84(1-3):37-43 [11817694.001]
  • [Cites] FASEB J. 1988 Nov;2(14):2996-3002 [3181654.001]
  • [Cites] FASEB J. 1987 Dec;1(6):441-5 [3315807.001]
  • [Cites] Metabolism. 1988 Jan;37(1):61-7 [3336286.001]
  • [Cites] J Nutr. 1988 Mar;118(3):367-74 [3351634.001]
  • [Cites] Br J Nutr. 1986 May;55(3):603-11 [3676178.001]
  • [Cites] Ann Nutr Metab. 1987;31(1):9-17 [3827207.001]
  • [Cites] Q J Med. 1985 Feb;54(214):153-60 [3983357.001]
  • [Cites] Am J Clin Nutr. 1985 Sep;42(3):439-48 [4036848.001]
  • [Cites] Clin Chem. 1979 Aug;25(8):1487-91 [455691.001]
  • [Cites] Br J Anaesth. 2007 Jun;98(6):775-84 [17478454.001]
  • [Cites] Med Chem. 2007 May;3(3):281-4 [17504200.001]
  • [Cites] Free Radic Biol Med. 2007 Jun 15;42(12):1826-37 [17512462.001]
  • [Cites] FASEB J. 2007 Oct;21(12):3063-74 [17536041.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3764-73 [17666482.001]
  • [Cites] BMC Endocr Disord. 2007;7:5 [17678551.001]
  • [Cites] Thyroid. 2007 Jul;17(7):609-12 [17696828.001]
  • [Cites] J Nutr. 1968 Jan;94(1):6-12 [5638639.001]
  • [Cites] Indian J Med Res. 1977 Jun;65(6):865-70 [604264.001]
  • [Cites] Br J Nutr. 1978 Mar;39(2):297-306 [629920.001]
  • [Cites] Lancet. 1976 Dec 25;2(8000):1382-5 [63851.001]
  • [Cites] Am J Clin Nutr. 1984 Jul;40(1):26-35 [6741853.001]
  • [Cites] S Afr Med J. 1981 Nov 21;60(21):818-23 [7029735.001]
  • [Cites] Postgrad Med J. 1980 Dec;56(662):833-7 [7267493.001]
  • [Cites] Environ Health Perspect. 1995 Apr;103 Suppl 3:85-8 [7635118.001]
  • [Cites] Clin Chem. 1998 Aug;44(8 Pt 1):1764-6 [9702974.001]
  • [Cites] Pharmacol Res. 1998 Aug;38(2):93-6 [9721594.001]
  • [Cites] In Vivo. 1998 Nov-Dec;12(6):695-722 [9891234.001]
  • [Cites] J Nutr. 1999 Jan;129(1):174-80 [9915896.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):835-9 [9927654.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Apr;87(4):1687-91 [11932302.001]
  • [Cites] Biomed Environ Sci. 2002 Mar;15(1):48-57 [12046548.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jun 28;294(5):1161-8 [12074599.001]
  • [Cites] Am J Clin Nutr. 2002 Jul;76(1):100-6 [12081822.001]
  • [Cites] Biol Trace Elem Res. 2002 Jul;88(1):25-30 [12117262.001]
  • [Cites] Proc Nutr Soc. 2002 May;61(2):203-15 [12133202.001]
  • [Cites] Nutrition. 2002 Oct;18(10):872-9 [12361782.001]
  • [Cites] Clin Exp Immunol. 2003 Mar;131(3):398-404 [12605691.001]
  • [Cites] Eur J Endocrinol. 2003 Mar;148(3):309-15 [12611611.001]
  • [Cites] Intern Med. 2003 Feb;42(2):154-7 [12636234.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):389-93 [12656658.001]
  • [Cites] Lancet. 2003 Apr 5;361(9364):1226 [12686067.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 May;58(5):550-5 [12699435.001]
  • [Cites] Free Radic Biol Med. 2003 May 15;34(10):1263-70 [12726914.001]
  • [Cites] Biol Trace Elem Res. 2003 Summer;93(1-3):9-18 [12835485.001]
  • [Cites] Int J Vitam Nutr Res. 2003 May;73(3):181-6 [12847994.001]
  • [Cites] Clin Chim Acta. 2003 Aug;334(1-2):163-71 [12867288.001]
  • [Cites] Pathologe. 2003 Sep;24(5):339-47 [12961022.001]
  • [Cites] J Trace Elem Electrolytes Health Dis. 1991 Dec;5(4):265-7 [1822335.001]
  • [Cites] Am J Clin Nutr. 1991 Jan;53(1):120-5 [1984336.001]
  • [Cites] Am J Clin Nutr. 1991 Jan;53(1):126-31 [1984337.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Mar;70(3):788-91 [2307731.001]
  • [Cites] Crit Care Med. 1990 Apr;18(4):442-6 [2318056.001]
  • [Cites] Lancet. 1989 May 20;1(8647):1096-100 [2566049.001]
  • [Cites] Am J Clin Nutr. 1989 May;49(5):854-61 [2718920.001]
  • [Cites] Am J Clin Nutr. 1989 May;49(5):862-9 [2718921.001]
  • [Cites] Int J Epidemiol. 1989 Mar;18(1):45-9 [2722382.001]
  • [Cites] J Trace Elem Med Biol. 1999 Jul;13(1-2):34-9 [10445216.001]
  • [Cites] Annu Rev Nutr. 1999;19:1-16 [10448514.001]
  • [Cites] Am J Clin Nutr. 1999 Nov;70(5):896-903 [10539752.001]
  • [Cites] Environ Health Perspect. 2000 Jan;108(1):67-71 [10620526.001]
  • [Cites] J Nutr. 2000 Feb;130(2S Suppl):483S-484S [10721934.001]
  • [Cites] J Nutr. 2000 May;130(5S Suppl):1447S-54S [10801958.001]
  • [Cites] Am J Clin Nutr. 2000 Jun;71(6 Suppl):1676S-81S [10837315.001]
  • [Cites] J Infect Dis. 2000 Sep;182 Suppl 1:S5-10 [10944478.001]
  • (PMID = 18221503.001).
  • [ISSN] 1472-6823
  • [Journal-full-title] BMC endocrine disorders
  • [ISO-abbreviation] BMC Endocr Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2266752
  •  go-up   go-down


59. Anderson CE, Graham C, Herriot MM, Kamel HM, Salter DM: CD98 expression is decreased in papillary carcinoma of the thyroid and Hashimoto's thyroiditis. Histopathology; 2009 Dec;55(6):683-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD98 expression is decreased in papillary carcinoma of the thyroid and Hashimoto's thyroiditis.
  • CD98 expression is increased in a variety of carcinomas but its distribution in the normal and neoplastic thyroid gland has not been reported.
  • The aim was to examine the immunohistochemical expression of CD98 in normal and diseased thyroid tissue.
  • METHODS AND RESULTS: One hundred and forty thyroid cases were selected from the archives of the Department of Pathology, including normal controls, neoplasms (follicular adenoma, follicular carcinoma and papillary carcinoma) and non-neoplastic conditions (multinodular goitre, Graves' disease and Hashimoto's thyroiditis).
  • In normal thyroid, there was moderately strong expression of CD98 in the lateral cell membranes of follicular cells.
  • A similar pattern of expression was seen in follicular adenoma, minimally invasive follicular carcinoma, multinodular goitre and Graves' disease.
  • In most cases of papillary carcinoma and in the inflamed areas of Hashimoto's thyroiditis, expression of CD98 was decreased.
  • CONCLUSIONS: CD98 expression is down-regulated in thyroid papillary carcinoma; this may relate to the better prognosis associated with many of these tumours.
  • [MeSH-major] Antigens, CD98 / metabolism. Carcinoma, Papillary / metabolism. Hashimoto Disease / metabolism. Thyroid Gland / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenoma / metabolism. Down-Regulation. Graves Disease / metabolism. Humans. Immunohistochemistry. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922591.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD98
  •  go-up   go-down


60. Sobrinho-Simões M, Máximo V, Castro IV, Fonseca E, Soares P, Garcia-Rostan G, Oliveira MC: Hürthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance. Int J Surg Pathol; 2005 Jan;13(1):29-35
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hürthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance.
  • The etiopathogenesis and the classification of oncocytic (Hürthle cell) tumors of the thyroid is reviewed with an emphasis on the role played by mitochondrial and nuclear genetic abnormalities that interfere with mitochondrial function.
  • Oxyphilia is classified into primary or secondary and the so-called Hürthle cell carcinoma is divided into oncocytic (Hürthle cell) variants of papillary and follicular carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735852.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  • [Number-of-references] 19
  •  go-up   go-down


61. Karslioğlu Y, Celasun B, Günhan O: Contribution of morphometry in the differential diagnosis of fine-needle thyroid aspirates. Cytometry B Clin Cytom; 2005 May;65(1):22-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of morphometry in the differential diagnosis of fine-needle thyroid aspirates.
  • BACKGROUND: Cytologic discrimination of cellular nodules, follicular adenoma, and follicular carcinoma in the thyroid is problematic.
  • Some sophisticated tools, such as microarrays, offer great potential but lack accompanying morphologic information.
  • METHODS: One hundred twelve samples obtained from patients with lesions histopathologically diagnosed as nodular goiter, follicular adenoma, follicular carcinoma, and papillary carcinoma were used.
  • In the second, a subset of data representing the most extreme values of variables was extracted from the entire dataset to simulate the "selection procedure" performed during conventional morphologic examination.
  • CONCLUSIONS: Morphologic examination is based primarily on selection.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Cell Biology. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenoma / diagnosis. Analysis of Variance. Carcinoma / diagnosis. Carcinoma, Papillary / diagnosis. Cell Nucleus / metabolism. Diagnosis, Differential. Goiter / diagnosis. Humans. Image Processing, Computer-Assisted. Multivariate Analysis. Sensitivity and Specificity. Software. Statistics as Topic / methods. Thyroid Diseases / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15779051.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Braunschweig T, Kaserer K, Chung JY, Bilke S, Krizman D, Knezevic V, Hewitt SM: Proteomic expression profiling of thyroid neoplasms. Proteomics Clin Appl; 2007 Mar;1(3):264-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic expression profiling of thyroid neoplasms.
  • Thyroid cancer is the most common endocrine neoplasm with multiple histologic subtypes, each associated with different treatments and outcomes.
  • Differentiating benign neoplasms such as follicular adenomas from malignant entities such as follicular carcinomas and papillary carcinoma can be challenging.
  • To define the proteomic profile of different thyroid tumors, we screened an antibody array of 330 features against five thyroid neoplasms: follicular adenoma, follicular carcinoma, papillary carcinoma, anaplastic carcinoma, and medullary carcinoma as well as normal thyroid epithelium.
  • Eight candidate biomarkers; c-erbB-2, Stat5a, Annexin IV, IL-11, RARα, FGF7, Caspase 9, and phospho-c-myc were identified as differentially expressed on the antibody array, and validated with immunohistochemistry on tissue microarrays, with a total of 144 samples of the same variety of thyroid neoplasms.
  • Analysis revealed c-erbB-2, Annexin IV, and Stat5a have potential clinical utility to differentiate follicular adenoma, follicular carcinoma, and papillary carcinoma from each other.
  • By using an antibody array as a discovery platform and a tissue microarray as a first step in validation on a large number of specimens, we have identified new markers that have potential utility in the diagnosis of thyroid neoplasms.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • (PMID = 21136677.001).
  • [ISSN] 1862-8346
  • [Journal-full-title] Proteomics. Clinical applications
  • [ISO-abbreviation] Proteomics Clin Appl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Xu F, Liu B, Chen XY, Zhou EX, Fan DF, Ma Y, Tang ZH: [Diagnosis and therapy of childhood thyroid carcinoma: clinical analysis of 12 cases]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Feb;11(2):120-3
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy of childhood thyroid carcinoma: clinical analysis of 12 cases].
  • OBJECTIVE: To explore the clinical characteristics, diagnosis and therapy of thyroid carcinoma in children.
  • METHODS: Clinical data of 12 children under the age of 14 years, diagnosed as thyroid carcinoma between August 1998 and August 2008, were reviewed.
  • RESULTS: A hard thyroid mass was observed in 10 out of 12 children with thyroid carcinoma, but only one out of 15 children with benign thyroid tumor (<0.05).
  • The rate of cervical lymph node metastasis in children with thyroid carcinoma was significantly higher than that in children with benign thyroid tumor (<0.05).
  • There was no significant difference in the final diagnostic rate of thyroid carcinoma between ultrasonography and CT scans (75% vs 83%; >0.05).
  • All of 12 cases were pathologically confirmed as differentiated thyroid carcinoma, including papillary carcinoma (7 cases), follicular carcinoma (3 cases) and papillary-follicular carcinoma (2 cases).
  • CONCLUSIONS: Childhood thyroid carcinoma is mostly differentiated and characterized by hard thyroid mass and cervical lymph node metastasis.
  • A combination of ultrasonography and CT is helpful to the diagnosis of childhood thyroid carcinoma.
  • The treatment outcome may be satisfactory by optimal therapy in children with thyroid carcinoma.
  • [MeSH-major] Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222949.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


64. Ganguly R, Mitra S, Datta AK: Synchronous occurrence of anaplastic, follicular and papillary carcinomas with follicular adenoma in thyroid gland. Indian J Pathol Microbiol; 2010 Apr-Jun;53(2):337-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of anaplastic, follicular and papillary carcinomas with follicular adenoma in thyroid gland.
  • Various combinations of thyroid carcinomas have been reported including those between different cancers of follicular cell origin and those between follicular and C-cell histogenesis.
  • Accordingly, anaplastic carcinomas have been seen to coincide with simultaneous papillary and follicular cancers.
  • We report a case of composite anaplastic and papillary cancer on one thyroid lobe with a follicular carcinoma in the other lobe in a female patient aged 64 years.
  • The patient also had a separate and independent follicular adenoma in the same lobe as the composite anaplastic and papillary carcinoma.
  • The papillary carcinoma was continuous with the anaplastic carcinoma.
  • The common follicular cell origin will explain the concurrent presence of all these cancers.
  • This could result from the dedifferentiation of a pre-existing differentiated carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / complications. Adenoma / complications. Carcinoma / complications. Carcinoma, Papillary / complications. Thyroid Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Pathol Microbiol. 2011 Apr-Jun;54(2):434-5 [21623130.001]
  • [CommentIn] Indian J Pathol Microbiol. 2011 Apr-Jun;54(2):414-5; author reply 415 [21623114.001]
  • (PMID = 20551551.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


65. Dănilă R, Andriescu L, Grigorovici A, Dragomir C, Găluşcă B, Vulpoi C, Ungureanu C, Mogoş V: [Differentiated thyroid cancer--staging and prognostic systems]. Rev Med Chir Soc Med Nat Iasi; 2005 Jan-Mar;109(1):71-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differentiated thyroid cancer--staging and prognostic systems].
  • Differentiated thyroid cancer (DTC), including papillary and follicular carcinoma with histological variants, has an excellent prognosis; nevertheless a subset of these tumours is clinically aggressive and, in some patients, fatal.
  • In addition to the widely accepted TNM classification, recognition of significant risk factors and developing of staging systems, such as AMES, AGES, MACIS, MSKCC and NTCTCS, has helped to identify the patients with a potential aggressive course of the disease and high risk of recurrence.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / surgery. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / surgery
  • [MeSH-minor] Carcinoma, Papillary, Follicular / surgery. Humans. Lymph Node Excision. Neoplasm Staging. Prognosis. Risk Factors. Thyroidectomy / methods

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607831.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 23
  •  go-up   go-down


66. Donckier JE, Mertens-Strijthagen J, Flamion B: Role of the endothelin axis in the proliferation of human thyroid cancer cells. Clin Endocrinol (Oxf); 2007 Oct;67(4):552-6
Hazardous Substances Data Bank. BROMODEOXYURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the endothelin axis in the proliferation of human thyroid cancer cells.
  • ET-1 axis is overexpressed in thyroid carcinoma.
  • We investigated the expression and the production of ET-1 by thyroid cancer cells as well as the effect of ET-1 receptor antagonism on cell proliferation.
  • DESIGN: Human papillary and follicular thyroid carcinoma cell lines were cultured.
  • MEASUREMENTS: (i) Prepro-ET-1, ET-1 receptors (ETA R and ETB R) and ET-1 converting enzyme (ECE) by reverse transcriptase polymerase chain reaction (RT-PCR);.
  • RESULTS: RT-PCR detected the presence of mRNA for prepro-ET-1, ETA R and ECE in papillary and follicular carcinoma cells.
  • ETB R was only expressed by follicular cells.
  • ETA R antagonism with atrasentan reduced cell proliferation by 16% in papillary carcinoma cells (P < 0.05) and by 51% in follicular carcinoma cells (P < 0.001).
  • CONCLUSIONS: Papillary and follicular carcinoma cells express all components of the ET-1 axis.
  • ETA R antagonism exerts antiproliferative effects, which opens up new therapeutic perspectives in thyroid carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / pathology. Endothelin-1 / physiology. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561979.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Endothelin A Receptor Antagonists; 0 / Endothelin-1; 0 / Pyrrolidines; 0 / RNA, Messenger; 0 / Receptor, Endothelin A; 0 / Receptor, Endothelin B; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.71 / endothelin-converting enzyme; G34N38R2N1 / Bromodeoxyuridine; V6D7VK2215 / atrasentan; VC2W18DGKR / Thymidine
  •  go-up   go-down


67. Elsheikh TM, Asa SL, Chan JK, DeLellis RA, Heffess CS, LiVolsi VA, Wenig BM: Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol; 2008 Nov;130(5):736-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma.
  • Distinguishing follicular variant of papillary carcinoma (FVPC) from follicular adenoma and follicular carcinoma can be difficult if nuclear features of papillary carcinoma are not well developed or only focally present.
  • We assessed interobserver and intraobserver agreement among 6 thyroid experts by using 15 cases in which original pathologists suspected FVPC.
  • [MeSH-major] Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / pathology. Adenoma / diagnosis. Adenoma / pathology. Adult. Cell Nucleus / pathology. Diagnostic Errors / prevention & control. Female. Humans. Male. Middle Aged. Observer Variation. Pathology, Surgical / standards

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Pathol. 2008 Nov;130(5):683-6 [18854259.001]
  • (PMID = 18854266.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Roth LM, Miller AW 3rd, Talerman A: Typical thyroid-type carcinoma arising in struma ovarii: a report of 4 cases and review of the literature. Int J Gynecol Pathol; 2008 Oct;27(4):496-506
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Typical thyroid-type carcinoma arising in struma ovarii: a report of 4 cases and review of the literature.
  • In this article, we report 3 cases of papillary and 1 of follicular thyroid carcinoma; 2 of these cases were associated with mature cystic teratoma.
  • In regard to the occurrence of thyroid-type carcinoma in struma ovarii, precise terminology should be used, and the expression malignant struma ovarii was avoided as a diagnostic term.
  • Upon review of the literature, papillary carcinoma and follicular carcinoma are the most frequent types of malignancy to occur in ovarian struma; other forms of thyroid carcinoma occur only rarely.
  • The diagnostic criteria for cases of papillary carcinoma are similar to those described in the cervical thyroid gland and are based primarily on nuclear and architectural features.
  • In reference to follicular carcinoma, invasion into the surrounding ovarian tissue, vascular invasion, or metastasis is evidence of malignancy.
  • Histological malignancy in a struma does not necessarily equate with biological malignancy, and the majority of thyroid-type carcinomas do not spread beyond the ovary.
  • Occasionally, metastases of ovarian struma have an innocuous histological appearance, and such cases are referred to as highly differentiated follicular carcinoma of ovarian origin (HDFCO).
  • Because its histological appearance resembles that of nonneoplastic thyroid, HDFCO characteristically cannot be diagnosed until the neoplasm spreads beyond the ovary.
  • In this article, we apply the term typical thyroid carcinoma to those forms of thyroid malignancy arising in ovarian struma that closely resemble the types described in the cervical thyroid gland to distinguish them from HDFCO.
  • Typical follicular carcinoma is more aggressive than the somewhat more common papillary carcinoma, and HDFCO is the least aggressive of these tumor types.
  • Cases of thyroid-type carcinoma arising in the ovary sometimes lack evidence of preexisting struma.
  • The more aggressive thyroid-type neoplasms can arise in thyroid tissue within a mature cystic teratoma, or they may overgrow and replace the struma.
  • Primary thyroid-type carcinoma must be distinguished from rare instances of ovarian metastases that originate in the cervical thyroid gland and the less differentiated forms from other ovarian neoplasms such as clear cell adenocarcinoma and tumors with an oxyphilic appearance.
  • In the differential diagnosis with other ovarian neoplasms, cases of thyroid-type carcinoma associated with strumal carcinoid should not be diagnosed as malignant strumal carcinoid because the latter diagnosis might lead to suboptimal therapy.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoid Tumor / pathology. Carcinoma, Papillary / pathology. Ovarian Neoplasms / pathology. Struma Ovarii / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753973.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Xu L, Zhong F, Guo FF, Zhao WJ, Sun XR, Wei XF: [Expression of motilin and its precursor mRNA in normal parenchyma, benign and malignant tumors of human thyroid]. Zhonghua Bing Li Xue Za Zhi; 2008 Apr;37(4):243-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of motilin and its precursor mRNA in normal parenchyma, benign and malignant tumors of human thyroid].
  • OBJECTIVE: To investigate the expression of motilin and its precursor mRNA in normal human thyroid.
  • To compare the expression differences of motilin and it precursor mRNA between normal thyroid and intestines.
  • To study the expression of motilin and its precursor mRNA in human thyroid tumors and their clinical implications.
  • METHODS: RT-PCR, Southern blot and molecular cloning were used to detect motilin transcript expression in human thyroid and mucous membrane of small intestine.
  • Real-time PCR and immunohistochemical techniques were used to quantify motilin precursor mRNA and motilin peptide in thyroid tissue samples including adenoma, medullary carcinoma, follicular carcinoma, papillary carcinoma and nodular goiter. RESULTS:.
  • (1) The expression of motilin and its precursor mRNA in normal human thyroid was primarily in the thyroid C cells. (2) RT-PCR and Southern blot showed that motilin mRNA expressed in human thyroid was identical to that expressed in duodenum with identical sequence deposited in NCBI Genbank of America. (3) Immunohistochemistry, Western blot research and real-time PCR studies showed that motilin and its precursor mRNA were expressed in normal and tumor tissues of human thyroid.
  • Thyroid tumors (acidophilic adenoma, medullary carcinoma, follicular carcinoma, papillary carcinoma and nodular goiter) showed intense and diffuse immunostaining for motilin peptide.
  • Moreover, the expression of motilin and its precursor mRNA in thyroid medullar carcinoma and acidophilic adenoma were significantly higher than those of normal thyroid tissue (P < 0.05).
  • The expression in thyroid follicular and papillary carcinomas were significantly lower than those of normal thyroid tissue (P < 0.05).
  • There was no difference of the expression between nodular goiter and normal thyroid tissue (P > 0.05).
  • CONCLUSIONS: Motilin peptide and its precursor mRNA are expressed in C cells of human thyroid.
  • The expressions of both motilin and its precursor mRNA in thyroid medullary carcinoma and acidophilic adenoma are significantly increased.
  • In contrast, their expressions in thyroid follicular and papillary carcinomas are significantly decreased.
  • Motilin may regulate physiological functions of the thyroid through parafollicular cells.
  • Motilin may be involved in the pathogenesis of medullary carcinoma and acidophilic adenoma of the thyroid.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Motilin / metabolism. RNA Precursors / metabolism. RNA, Messenger / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adult. Aged. Carcinoma, Medullary / genetics. Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Female. Humans. Intestines / metabolism. Male. Middle Aged. Nervous System Neoplasms / metabolism. Thyroid Gland / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18844033.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA Precursors; 0 / RNA, Messenger; 52906-92-0 / Motilin
  •  go-up   go-down


70. Handkiewicz-Junak D, Czarniecka A, Jarzab B: Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol; 2010 Jun 30;322(1-2):8-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions.
  • Gene expression profiling shows that, by gene signature, the difference between BRAF-positive and BRAF-negative PTC is so distinct that BRAF-positive cancer may be regarded as a molecular subtype of papillary thyroid cancer (PTC).
  • We estimate that 31% of all PTC patients and 39% of those diagnosed with stage I-II disease will face the risk of overtreatment if the decision will be based on the BRAF-positivity of their tumors.
  • Considering this, in the review we summarize the present status of knowledge on other prognosis-related gene expression changes in papillary and follicular cancer and relate them to he tumor's biology.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Carcinoma, Papillary / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Genetic Predisposition to Disease. Humans. Mutation. Prognosis. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins B-raf / metabolism. ras Proteins / genetics. ras Proteins / metabolism

  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20138116.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 259
  •  go-up   go-down


71. Guignard R, Truong T, Rougier Y, Baron-Dubourdieu D, Guénel P: Alcohol drinking, tobacco smoking, and anthropometric characteristics as risk factors for thyroid cancer: a countrywide case-control study in New Caledonia. Am J Epidemiol; 2007 Nov 15;166(10):1140-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alcohol drinking, tobacco smoking, and anthropometric characteristics as risk factors for thyroid cancer: a countrywide case-control study in New Caledonia.
  • Exceptionally high incidence rates of thyroid cancer are observed in New Caledonia, particularly in Melanesian women.
  • To investigate further the etiology of thyroid cancer and to clarify the reasons of this elevated incidence, the authors conducted a countrywide population-based case-control study in this multiethnic population.
  • The study included 332 cases with histologically verified papillary or follicular carcinoma (293 women and 39 men) diagnosed in 1993-1999 and 412 population controls (354 women and 58 men) frequency matched by gender and 5-year age group.
  • Thyroid cancer was negatively associated with tobacco smoking and alcohol drinking, but no inverse dose-response relation was observed.
  • Height was positively associated with thyroid cancer, particularly in men.
  • This study clarifies the role of overweight for thyroid cancer in postmenopausal women.
  • Because of the high prevalence of obesity among Melanesian women of New Caledonia, this finding may explain in part the exceptionally elevated incidence of thyroid cancer in this group.
  • [MeSH-major] Adenocarcinoma, Follicular / etiology. Alcohol Drinking / adverse effects. Body Size. Carcinoma, Papillary / etiology. Smoking / adverse effects. Thyroid Neoplasms / etiology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2005 Jun 1;161(11):1056-65 [15901626.001]
  • [Cites] Int J Cancer. 2005 Sep 1;116(3):433-8 [15818623.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):366-70 [16832414.001]
  • [Cites] Eur J Cancer Prev. 2007 Feb;16(1):62-70 [17220706.001]
  • [Cites] Epidemiology. 2000 Jan;11(1):49-54 [10615843.001]
  • [Cites] Cancer Causes Control. 2000 Feb;11(2):137-44 [10710197.001]
  • [Cites] Eur J Cancer. 2000 Oct;36(15):1969-73 [11000579.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Mar;86(3):1072-7 [11238488.001]
  • [Cites] Int J Cancer. 2001 Sep 1;93(5):745-50 [11477590.001]
  • [Cites] Thyroid. 2002 Feb;12(2):141-9 [11916283.001]
  • [Cites] Thyroid. 2002 Feb;12(2):163-8 [11916286.001]
  • [Cites] Br J Cancer. 2002 Jun 5;86(11):1745-50 [12087461.001]
  • [Cites] Ann Epidemiol. 2002 Aug;12(6):395-401 [12160598.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1762-8 [12175693.001]
  • [Cites] J Endocrinol. 2002 Dec;175(3):571-6 [12475368.001]
  • [Cites] Cancer Causes Control. 2003 Oct;14(8):773-85 [14674742.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] J Natl Cancer Inst. 1984 Sep;73(3):575-81 [6590909.001]
  • [Cites] Cancer Res. 1987 Jan 1;47(1):292-5 [3791213.001]
  • [Cites] J Natl Cancer Inst. 2005 May 18;97(10):724-32 [15900042.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Feb;62(2):156-62 [15670190.001]
  • [Cites] Thyroid. 2004 Dec;14(12):1056-60 [15650358.001]
  • [Cites] Ann Surg Oncol. 2004 Dec;11(12):1093-7 [15576834.001]
  • [Cites] Br J Cancer. 1987 Feb;55(2):191-5 [3814488.001]
  • [Cites] J R Soc Health. 1997 Dec;117(6):355-8 [9519672.001]
  • [Cites] Int J Obes Relat Metab Disord. 1997 Jan;21(1):61-6 [9023603.001]
  • [Cites] Br J Cancer. 1997;75(3):451-6 [9020497.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Aug;20(5):954-60 [8865974.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jun;5(6):425-31 [8781737.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):193-9 [7606193.001]
  • [Cites] Am J Epidemiol. 1995 Apr 15;141(8):741-6 [7709916.001]
  • [Cites] Eur J Cancer Prev. 1994 Nov;3(6):481-8 [7858480.001]
  • [Cites] J Natl Cancer Inst. 1987 Jul;79(1):1-12 [3474436.001]
  • [Cites] Int J Epidemiol. 1989 Sep;18(3):578-84 [2807659.001]
  • [Cites] Acta Chir Scand. 1989 Jun-Jul;155(6-7):317-20 [2816215.001]
  • [Cites] Eur J Cancer. 1991;27(1):85-8 [1826448.001]
  • [Cites] Cancer Causes Control. 1990 Nov;1(3):223-34 [2102295.001]
  • [Cites] Br J Cancer. 1992 Dec;66(6):1180-4 [1457362.001]
  • [Cites] Cancer Causes Control. 1993 Jan;4(1):11-6 [8431525.001]
  • [Cites] IARC Sci Publ. 1992;(120):45-173 [1284606.001]
  • [Cites] Eur J Cancer Prev. 1993 Jul;2(4):345-9 [8358287.001]
  • [Cites] Am J Epidemiol. 1993 Oct 1;138(7):482-91 [8213752.001]
  • [Cites] Cancer Causes Control. 1993 Sep;4(5):431-40 [8218875.001]
  • (PMID = 17855390.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ HALMS176743; NLM/ PMC2220030
  •  go-up   go-down


72. Hay ID: Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol; 2006 Dec 15;94(8):692-700
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma.
  • Radioiodine remnant ablation (RRA) was developed in the 1960s to "complete a thyroidectomy" in the initial management of papillary and follicular thyroid cancer.
  • By the 1990s, it was claimed that RRA diminished recurrence rates in follicular cell-derived cancer (FCDC) patients and decreased the cause-specific mortality (CSM) in patients more than 40 years old at initial surgery.
  • [MeSH-major] Adenocarcinoma, Follicular / radiotherapy. Carcinoma, Papillary, Follicular / radiotherapy. Iodine Radioisotopes / therapeutic use. Thyroid Neoplasms / radiotherapy. Thyroidectomy / methods
  • [MeSH-minor] Adult. Catheter Ablation. Combined Modality Therapy. Humans. Neoplasm Staging. Postoperative Care. Risk Assessment. Survival Rate. Thyroid Hormones / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131429.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Thyroid Hormones
  • [Number-of-references] 62
  •  go-up   go-down


73. Di Cristofaro J, Marcy M, Vasko V, Sebag F, Fakhry N, Wynford-Thomas D, De Micco C: Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum Pathol; 2006 Jul;37(7):824-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant.
  • Although the follicular variant of papillary thyroid carcinoma (FVPTC) has been classified as a papillary cancer based on nuclear features, its follicular growth pattern and potential for hematogenous spread are more characteristic of follicular carcinoma.
  • To gain insight into the biologic nature of FVPTC, we compared genetic alterations characteristic of papillary and follicular thyroid carcinomas in 24 FVPTCs and 26 classic PTC (CPTCs).
  • Based on these findings, we concluded that ras mutation correlates with follicular differentiation of thyroid tumors whereas ret activation is associated with papillary nuclei but not with papillary architecture. ret activation is not exclusive of ras or BRAF mutation, whereas ras and BRAF mutations are mutually exclusive.
  • The implications of these results for follicular and papillary carcinogenesis are discussed.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Papillary / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784981.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


74. Tsilchorozidou T, Vafiadou E, Yovos JG, Romeo G, McKay J, Lesueur F, Bonora E: A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci. Thyroid; 2005 Dec;15(12):1349-54
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci.
  • The familial form of nonmedullary thyroid carcinoma (FNMTC) has been recognized as a distinct clinical entity and is characterized by multifocality and a more severe phenotype than its sporadic counterpart.
  • The majority of FNMTC pedigrees are small in size, show variable modes of inheritance, and may present with a variety of additional benign thyroid disorders.
  • This locus appears particular relevant to families with at least one case of the follicular variant of papillary thyroid cancer (fvPTC).
  • We describe the clinical and pathologic characteristics of a large three-generation fPTC kindred, with two of the four PTC patients presented with the follicular variant of PTC.
  • From the PTC patients, one had MNG and fvPTC, one MNG, lymphocytic thyroiditis and papillary pattern of PTC, one lymphocytic thyroiditis and fvPTC, and one MNG and papillary pattern of PTC.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Carcinoma, Papillary / genetics. Genetic Predisposition to Disease. Thyroid Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405407.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. ul Haq RN, Khan BA, Chaudhry IA: Prevalence of malignancy in goitre--a review of 718 thyroidectomies. J Ayub Med Coll Abbottabad; 2009 Oct-Dec;21(4):134-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Thyroid malignancies are a heterogeneous group oftumours which show considerable variability in biological behaviour, histological appearances and response to therapy.
  • Thyroid cancer is uncommon and represents only 1% of all malignancies.
  • Prevalence of papillary and follicular carcinoma was 33.33% each.
  • Anaplastic carcinoma was found in 23.81% of patients followed by Hurthle cell carcinoma in 9.53% of patients.
  • CONCLUSION: All postoperative thyroid specimens should be subjected to histopathology.
  • Prevalence of follicular carcinoma and anaplastic carcinoma is relatively higher in our country due to high incidence of iodine deficiency goitre.
  • [MeSH-major] Goiter, Endemic / epidemiology. Thyroid Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Child. Female. Humans. Male. Middle Aged. Pakistan / epidemiology. Prevalence. Prospective Studies. Thyroidectomy. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21067046.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


76. Vorländer C, Lienenlüke RH, Wahl RA: [Lymph node dissection in papillary and follicular thyroid cancer]. Chirurg; 2008 Jun;79(6):564-70
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymph node dissection in papillary and follicular thyroid cancer].
  • BACKGROUND: There is still unresolved debate about the optimal surgical management of papillary (PTC) and follicular (FTC) thyroid cancer regarding lymph node dissection.
  • PATIENTS AND METHODS: This study is based on 626 patients with PTC and 191 with FTC from a group of 1062 own patients with thyroid malignancies.
  • [MeSH-major] Adenocarcinoma, Follicular / surgery. Carcinoma, Papillary / surgery. Lymph Node Excision / methods. Thyroid Neoplasms / surgery. Thyroidectomy / methods


77. Gombos K, Zele E, Kiss I, Varjas T, Puskás L, Kozma L, Juhász F, Kovács E, Szanyi I, Ember I: Characterization of microarray gene expression profiles of early stage thyroid tumours. Cancer Genomics Proteomics; 2007 Nov-Dec;4(6):403-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of microarray gene expression profiles of early stage thyroid tumours.
  • PATIENTS AND METHODS: A high-density oligonucleotide array with 20,000 human gene-specific oligonucleotide was used to analyze benign and early-stage malignant thyroid tumours of epithelial origin: follicular adenoma, follicular carcinoma and papillary carcinoma, compared to normal thyroid tissue.
  • Our findings suggest that modulation of NF-kappaB signalling plays a crucial role in early thyroid carcinogenesis.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Microarray Analysis. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18204203.001).
  • [ISSN] 1109-6535
  • [Journal-full-title] Cancer genomics & proteomics
  • [ISO-abbreviation] Cancer Genomics Proteomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / NF-kappa B
  •  go-up   go-down


78. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M: Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab; 2006 Aug;91(8):2892-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
  • AIM: The goal of this study was to estimate the cumulative activity of (131)I to be administered to patients with distant metastases from thyroid carcinoma.
  • METHODS: A total of 444 patients were treated from 1953-1994 for distant metastases from papillary and follicular thyroid carcinoma: 223 had lung metastases only, 115 had bone metastases only, 82 had both lung and bone metastases, and 24 had metastases at other sites.
  • Treatment consisted of the administration of 3.7 GBq (100 mCi) (131)I after withdrawal of thyroid hormone treatment, every 3-9 months during the first 2 yr and then once a year until the disappearance of any metastatic uptake.
  • RESULTS: Negative imaging studies (negative total body (131)I scans and conventional radiographs) were attained in 43% of the 295 patients with (131)I uptake; more frequently in those who were younger, had well-differentiated tumors, and had a limited extent of disease.
  • [MeSH-major] Adenocarcinoma, Follicular / radiotherapy. Carcinoma, Papillary / radiotherapy. Iodine Radioisotopes / therapeutic use. Neoplasm Metastasis / radiotherapy. Thyroid Neoplasms / radiotherapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Endocrinol Metab. 2006 Nov;2(11):610-1 [17082807.001]
  • (PMID = 16684830.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


79. Reschini E, Ferrari C, Castellani M, Matheoud R, Paracchi A, Marotta G, Gerundini P: The trapping-only nodules of the thyroid gland: prevalence study. Thyroid; 2006 Aug;16(8):757-62
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The trapping-only nodules of the thyroid gland: prevalence study.
  • The aim of this study was to determine the prevalence of trapping-only nodules of the thyroid gland.
  • The study was prospectively performed in patients bearing hot or warm thyroid nodules at pertechnetate scan in the presence of circulating thyrotropin (TSH) within the normal range.
  • Five had benign thyroid nodules, one follicular carcinoma, and one extrathyroid metastases of papillary-follicular carcinoma.
  • Despite controversy on this issue, trapping-only nodules of thyroid should be searched because they have risk of malignancy and must be differentiated from autonomous adenomas at the compensated stage.
  • [MeSH-major] Adenocarcinoma, Follicular / radionuclide imaging. Carcinoma / radionuclide imaging. Thyroid Neoplasms / radionuclide imaging. Thyroid Nodule / epidemiology. Thyroid Nodule / therapy. Thyrotropin / blood

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910877.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 9002-71-5 / Thyrotropin; A0730CX801 / Sodium Pertechnetate Tc 99m
  •  go-up   go-down


80. Di Tommaso L, Arizzi C, Roncalli M: [Well differentiated thyroid carcinoma: new perspectives and old dilemmas]. Ann Ital Chir; 2006 May-Jun;77(3):199-208
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Well differentiated thyroid carcinoma: new perspectives and old dilemmas].
  • The diagnosis of well differentiated carcinoma (i.e papillary carcinoma and follicular carcinoma) represents one of the most challenging issue in thyroid pathology.
  • 2) the management of small papillary tumour;.
  • 3) pathological classification of those tumours indeterminate for papillary or follicular nature.
  • There is general agreement that fine needle aspiration represent the best pre-operative diagnostic tool for thyroid nodules; foremost limits are represented by "not diagnostic" and 'follicular lesion, NOS".
  • The former should be repeated or, if suspicious for papillary lesion, improved with intra-operative apposition cytology; the latter should be deferred to histology with frozen section evaluation reserved to those institution with daily practice on this issue.
  • The management of papillary micro-carcinoma (i.e. papillary carcinoma smaller than 1 cm.) in the setting of an otherwise benign thyroid disease is a matter of debate, since several clinicians suggest to consider these as incidental findings thus avoiding additional treatment.
  • Recently this attitude has been supported by the proposal to regard these lesion as "tumour" and not carcinoma: available data on follow up seems to sustain and favour this approach.
  • There exist a group of well differentiated tumours of the thyroid lacking the criteria to be diagnosed either as papillary (i.e. nuclear grooves, nuclear pseudo-inclusion and nuclear clearing) or follicular (i.e. capsular or vascular invasion) carcinoma; for these lesion, whose behaviour (nodal or blood metastasis) can not be predicted, it has been suggested the term of well differentiated tumour of uncertain malignant potential.
  • Finally it has to be mentioned the possible role of molecular biology in the diagnosis of well differentiated thyroid carcinoma; indeed markers such as RET/PTC or PAX8/PPARgamma, which to date have been employed mainly in basic research, might represent useful diagnostic (and therapeutic) tools in the future.
  • [MeSH-major] Carcinoma. Thyroid Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17137034.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 46
  •  go-up   go-down


81. Demirag F, Cakir E, Aydin E, Kaya S, Akyurek N: Ectopic primary B cell lymphoma of the thyroid presenting as an anterior mediastinal mass. A case report. Acta Chir Belg; 2009 Nov-Dec;109(6):802-4
Genetic Alliance. consumer health - Thyroid Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic primary B cell lymphoma of the thyroid presenting as an anterior mediastinal mass. A case report.
  • Ectopic thyroid tumours arising in the mediastinum without connection to the cervical thyroid gland are very rare.
  • Follicular adenoma, papillary carcinoma and follicular carcinoma in the mediastinum has been reported, but primary ectopic thyroid B cell lymphoma has not been reported previously.
  • We report mediastinal primary ectopic thyroid large B cell lymphoma in an 80-year-old man.
  • [MeSH-major] Choristoma / pathology. Lymphoma, B-Cell / diagnosis. Mediastinal Neoplasms / diagnosis. Thyroid Gland

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20184075.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


82. Obara T: [Medullary thyroid carcinoma and other rare types of thyroid carcinoma]. Nihon Rinsho; 2007 Nov;65(11):2087-91
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Medullary thyroid carcinoma and other rare types of thyroid carcinoma].
  • Among 4 major traditional groups of thyroid carcinoma, papillary and follicular carcinomas are most common, and other forms, anaplastic and medullary carcinomas, are relatively rare.
  • The 2003 WHO histological classification of thyroid tumor separated 7 other malignant thyroid tumors into distinct pathological entities, such as poorly differentiated, squamous cell, mucinous carcinomas, carcinoma showing thymus-like differentiation (CASTLE), etc.
  • In this review, not only diagnostic and therapeutic strategies for the rare forms of thyroid carcinomas, specifically focussed on medullary carcinoma and CASTLE, but also their histogenetic abnormalities were discussed.
  • [MeSH-major] Carcinoma, Medullary. Thyroid Neoplasms
  • [MeSH-minor] Biomarkers, Tumor / blood. Calcitonin / blood. Carcinoma / pathology. Carcinoma / therapy. Cell Differentiation. Humans. Multiple Endocrine Neoplasia Type 2a. Mutation. Proto-Oncogene Proteins c-ret / genetics. Thymus Gland / cytology. Thymus Gland / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018575.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9007-12-9 / Calcitonin; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human
  • [Number-of-references] 17
  •  go-up   go-down


83. Lang BH, Lo CY, Chan WF, Lam AK, Wan KY: Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome. World J Surg; 2006 May;30(5):752-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome.
  • INTRODUCTION: The follicular variant of papillary thyroid carcinoma (FVPTC) is the most common histologic subtype of papillary thyroid carcinoma (PTC).
  • The two groups were compared in terms of clinicopathological features, treatment received, and outcome regarding recurrence and disease-specific survival.
  • The 10- and 15-year actuarial disease-specific survivals did not differ significantly between FVPTC and CPTC patients (96.2% versus 90.7% and 96.2% versus 89.1%, respectively).
  • CONCLUSIONS: Although patients with FVPTC had more favorable clinicopathologic features and a better tumor risk group profile, their long-term outcome was similar to that of CPTC patients.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Thyroid Neoplasms / pathology. Thyroidectomy / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680590.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Silberstein EB: Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med; 2007 Jul;48(7):1043-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
  • Detection of residual tissue after thyroidectomy for papillary or follicular thyroid carcinoma may be performed using diagnostic imaging with either (123)I or (131)I.
  • This study examines the outcomes of ablative (131)I therapy after diagnostic studies with either (123)I or (131)I to determine if the diagnostic dosages of these radionuclides used in our Thyroid Cancer Center reduce the efficacy of (131)I given for remnant ablation.
  • METHODS: Fifty patients with nonmetastatic papillary or follicular carcinoma of the thyroid received total thyroidectomy; this was followed by thyroid hormone withdrawal to achieve a serum thyroid-stimulating hormone level in excess of 30 microIU/mL.
  • Group 1 had diagnostic imaging with 14.8 MBq of (123)I followed by thyroid remnant ablation with 3.7 GBq of (131)I.
  • Successful ablation required a negative follow-up thyroid scan 6-8 mo after ablation and also an undetectable serum thyroglobulin level in the absence of antithyroglobulin antibodies.
  • CONCLUSION: If thyroid remnant stunning occurs due to 74 MBq (131)I used as a diagnostic agent before (131)I ablation, it has no significant clinical correlate, as it yields the same ablation rate as that which occurs after 14.8 MBq of (123)I used for imaging.
  • [MeSH-major] Adenocarcinoma, Follicular / radionuclide imaging. Carcinoma, Papillary / radionuclide imaging. Iodine Radioisotopes / therapeutic use. Radiopharmaceuticals / therapeutic use. Thyroid Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Thyroid Hormones / blood. Thyroidectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Nucl Med. 2008 Jan;49(1):166; author reply 166-7 [18165699.001]
  • (PMID = 17574976.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0 / Thyroid Hormones
  •  go-up   go-down


85. Tamaki H: [Thyroid carcinoma]. Gan To Kagaku Ryoho; 2005 Apr;32(4):561-5
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thyroid carcinoma].
  • Among thyroid carcinomas, thyroglobulin is a good tumor marker for differentiated carcinoma (papillary carcinoma, follicular carcinoma).
  • On the other hand, medullary thyroid caricima has a very sensitive and specific tumor marker, calcitonin.
  • In inherited medullary carcinoma (multiple endocrine neoplasia type 2), RET protooncogene analysis is the best for detecting early medullary thyroid carcinoma.
  • [MeSH-major] Biomarkers, Tumor / blood. Calcitonin / blood. Proto-Oncogene Proteins / genetics. Receptor Protein-Tyrosine Kinases / genetics. Thyroglobulin / blood. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Carcinoembryonic Antigen / blood. Carcinoma, Medullary / diagnosis. Carcinoma, Papillary / diagnosis. Enzyme-Linked Immunosorbent Assay. Humans. Immunoradiometric Assay. Multiple Endocrine Neoplasia Type 2b / diagnosis. Multiple Endocrine Neoplasia Type 2b / genetics. Proto-Oncogene Proteins c-ret. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15853229.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Proto-Oncogene Proteins; 9007-12-9 / Calcitonin; 9010-34-8 / Thyroglobulin; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Number-of-references] 8
  •  go-up   go-down


86. Matuszczyk A, Petersenn S, Bockisch A, Gorges R, Sheu SY, Veit P, Mann K: Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res; 2008 Mar;40(3):210-3
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium.
  • Twenty-two patients (mean age 61) with metastasizing, progressive, nonradioiodine-accumulating thyroid carcinoma of the follicular epithelium were treated with doxorubicin between 2000 and 2005.
  • Tumors were histologically classified as follicular in 15 patients (68%) and papillary in 7 patients (32%).
  • In addition, nine patients (mean age 51 years) with medullary thyroid carcinoma were treated with doxorubicin between 1997 and 2005.
  • In patients with papillary or follicular thyroid carcinoma, 5% had a partial regression over 6 months, 42% had stable disease for a median of 7 months (range: 1-22), and 53% had continuous progression established over 5 months (range: 1-11).
  • In patients with medullary thyroid carcinoma, 11% had a partial regression over 6 months followed by stable disease for 3 months, 11% had stable disease over 7 months, and 79% demonstrated progressive disease established over 5 months (range: 2-12).
  • Doxorubicin can be a valid chemotherapy option, especially for advanced or metastatic thyroid carcinoma of the follicular epithelium.
  • [MeSH-major] Adenocarcinoma, Follicular / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Doxorubicin / therapeutic use. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Medullary / drug therapy. Carcinoma, Medullary / radiography. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / radiography. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18348081.001).
  • [ISSN] 0018-5043
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


87. Musholt PB, Musholt TJ, Morgenstern SC, Worm K, Sheu SY, Schmid KW: Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot. World J Surg; 2008 May;32(5):722-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
  • BACKGROUND: The BRAF V600E mutation is the most prevalent genetic aberration in papillary thyroid carcinomas (PTCs), and it is found exclusively in RET/PTC-negative tumors.
  • In oncocytic (Hürthle cell, oxyphilic) thyroid tumors, the presence of RET/PTC rearrangements is associated with either the conventional papillary histotype or the "solid" Hürthle cell tumors, whereas all predominantly follicular oncocytic carcinomas do not harbor RET/PTC chimeras.
  • Although 12% of tumors of the follicular variant of PTC carry BRAF mutations, none of the few oncocytic follicular thyroid adenomas (oncoAd) or carcinomas (oncoFTC) published worldwide tested positive.
  • An aspired molecular-based classification of oncocytic thyroid tumors is in need of additional evidence on BRAF mutations in the follicular histotype.
  • METHODS: A series of 44 oncocytic thyroid tumors with well-documented clinicopathological data was subjected to BRAF mutation analysis (complete exon 15) by automated sequencing.
  • RESULTS: The series of oncocytic thyroid tumors consisted of 21 adenomas (oncoAds: 17 females, 4 males; mean age, 54.5 years; range, 27-80 years), 20 follicular carcinomas (oncoFTCs: 14 females, 6 males; mean age, 61.4 years; range, 39-80 years), and 3 "classic" papillary carcinomas (oncoPTCs: 3 females; mean age, 58.1 years; range, 46-70 years; 3x T2 tumors).
  • The follicular variants of oncocytic cancers are divided into 11x T2, 5x T3, and 4x T4 tumor stages (International Union Against Cancer [UICC] TNM 5th edition).
  • CONCLUSIONS: Our results add to the evidence that, in contrast to follicular variants of oncoPTCs, predominantly follicular oncocytic thyroid tumors harbor neither RET/PTC rearrangements nor BRAF mutations.
  • Furthermore, the findings support the concept that oncocytic neoplasms of the thyroid gland are oncocytic counterparts of the respective histotype (adenoma, FTC, PTC, or poorly differentiated thyroid carcinoma) rather than a separate tumor entity.
  • Molecular characterization of oncocytic thyroid malignancies for RET/PTC or BRAF genetic alterations may help with (preoperative) classification and prognostic evaluation of these tumors.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenoma, Oxyphilic / genetics. Carcinoma, Papillary / genetics. Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18235983.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


88. Ito Y, Hirokawa M, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A: Prognosis and prognostic factors of follicular carcinoma in Japan: importance of postoperative pathological examination. World J Surg; 2007 Jul;31(7):1417-24
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis and prognostic factors of follicular carcinoma in Japan: importance of postoperative pathological examination.
  • BACKGROUND: Follicular carcinoma is known to show a worse prognosis than papillary carcinoma because of distant metastasis in higher incidence.
  • However, few studies have been published regarding the prognosis of follicular carcinoma patients in Japan, which prompted us to investigate this issue.
  • METHODS: We examined the prognosis and whether and how various clinicopathological features have affected disease-free survival (DFS) and cause-specific survival (CSS) of 334 patients who underwent initial surgery for follicular carcinoma.
  • Poorly differentiated carcinoma and widely invasive carcinoma, together with some conventional prognostic factors, predicted poorer DFS of patients.
  • On multivariate analysis, poorly differentiated carcinoma was an independent prognostic factor for DFS.
  • Curative surgery and poorly differentiated carcinoma were recognized as independent prognostic factors.
  • CONCLUSIONS: We can hypothesize that follicular carcinoma in Japan is generally a nonaggressive disease with a good prognosis.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Differentiation. Disease-Free Survival. Female. Humans. Japan. Male. Middle Aged. Multivariate Analysis. Postoperative Period. Pressure. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17534542.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Porto T, Coelho I, Boavida J, Pereira C, Nunes JM, Mendonça D, Martins B, Sobrinho LG, Leite V: Association of HLA DQ4-DR8 haplotype with papillary thyroid carcinomas. Clin Endocrinol (Oxf); 2006 Feb;64(2):179-83
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of HLA DQ4-DR8 haplotype with papillary thyroid carcinomas.
  • OBJECTIVE: The association of the human leucocyte antigen (HLA) system with thyroid carcinomas is not clear.
  • We sought to relate HLA alleles to susceptibility to papillary thyroid carcinoma (PTC) and also to clinical and pathological characteristics of PTC patients.
  • DESIGN AND PATIENTS: The distribution of HLA in 181 unrelated Caucasian patients with PTC was compared to the HLA distribution in 315 normal controls, 31 patients with follicular carcinoma (FTC), 29 patients with lymphocytic thyroiditis (LT) and 50 patients with multinodular goitre (MNG), using a microlymphocytotoxicity assay.
  • CONCLUSIONS: We have typed the largest series of patients with thyroid carcinomas reported to date, and found that DR8 and DQ4 are independent susceptibility markers for PTC.
  • [MeSH-major] Carcinoma, Papillary / genetics. HLA Antigens / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Alleles. Genetic Markers. Genetic Predisposition to Disease. Goiter, Nodular / genetics. HLA-DQ Antigens / genetics. HLA-DR Antigens / genetics. HLA-DR Serological Subtypes. Haplotypes / genetics. Humans. Linkage Disequilibrium / genetics. Odds Ratio. Thyroiditis, Autoimmune / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Endocrinol (Oxf). 2006 Jun;64(6):715 [16712678.001]
  • (PMID = 16430717.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / HLA Antigens; 0 / HLA-DQ Antigens; 0 / HLA-DQ4 antigen; 0 / HLA-DR Antigens; 0 / HLA-DR Serological Subtypes; 0 / HLA-DR8 antigen
  •  go-up   go-down


90. Yoon JH, Kim EK, Hong SW, Kwak JY, Kim MJ: Sonographic features of the follicular variant of papillary thyroid carcinoma. J Ultrasound Med; 2008 Oct;27(10):1431-7
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic features of the follicular variant of papillary thyroid carcinoma.
  • OBJECTIVE: The purpose of this study was to evaluate the sonographic findings of the follicular variant of papillary thyroid carcinoma (FVPTC) and to assess the role of preoperative fine-needle aspiration biopsy (FNAB).
  • METHODS: The sonographic findings of 27 thyroid nodules in 26 patients (2 male and 24 female; mean age, 45 years) with surgically proven FVPTC were reviewed retrospectively.
  • Thyroid nodules with a single malignant finding as described above were classified as malignant.
  • Twenty-one of 24 diagnostic cytologic results (87.5%) were suspicious for papillary carcinoma (5 of 21 [20.8%]) or malignant (16 of 21 [66.7%]), whereas 3 lesions (12.5%) had benign results.
  • CONCLUSIONS: The follicular variant of papillary thyroid carcinoma tends to have relatively benign sonographic features, such as hypoechogenicity, well-defined margins, an oval shape, and no microcalcifications, but most lesions were correctly classified as malignant by both sonography and FNAB.
  • The possibility of FVPTC should be considered when thyroid nodules with a relatively benign sonographic appearance have suspicious or malignant FNAB results.
  • [MeSH-major] Adenocarcinoma, Follicular / ultrasonography. Adenocarcinoma, Papillary / ultrasonography. Thyroid Neoplasms / ultrasonography. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18809953.001).
  • [ISSN] 1550-9613
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Nelson KK, Gattuso P, Xu X, Prinz RA: Expression of the sonic hedgehog pathway molecules in synchronous follicular adenoma and papillary carcinoma of the thyroid gland in predicting malignancy. Surgery; 2010 Oct;148(4):654-60; discussion 660
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the sonic hedgehog pathway molecules in synchronous follicular adenoma and papillary carcinoma of the thyroid gland in predicting malignancy.
  • The Sonic Hedgehog pathway is required for normal thyroid gland development, but when activated as a result of gene mutation or overexpression, it may stimulate thyroid tumor cell proliferation.
  • This study determines whether 3 molecules, Patched, Smoothened, and Sonic Hedgehog, involved in the Sonic Hedgehog pathway are overexpressed equally in synchronous follicular thyroid adenoma and papillary thyroid carcinoma.
  • METHODS: Eighteen patients with synchronous follicular thyroid adenoma and papillary thyroid carcinoma underwent thyroidectomy.
  • Patched expression was detected in 5 of 13 (38%) follicular adenomas and 5 of 12 (42%) papillary carcinomas.
  • Smoothened was expressed in 4 of 13 (31%) follicular adenomas and 3 of 13 (23%) papillary carcinomas.
  • Sonic Hedgehog was expressed in 4 of 13 (31%) follicular adenomas and 11 of 13 (85%) papillary carcinomas.
  • CONCLUSION: Expression of the 3 molecules involved in the Sonic Hedgehog pathway was similar in follicular thyroid adenoma, but Sonic Hedgehog expression was a more sensitive indicator of malignancy in papillary thyroid carcinoma.
  • The Sonic Hedgehog molecule may become a diagnostic marker when the cytologic or histologic features are not characteristic of a papillary carcinoma.
  • Greater understanding of the Sonic Hedgehog pathway may provide molecular methods for preventing or treating papillary thyroid carcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Adenoma / metabolism. Hedgehog Proteins / biosynthesis. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasms, Multiple Primary. Predictive Value of Tests. Thyroid Gland / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20797751.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / SHH protein, human
  •  go-up   go-down


92. Williams MD, Suliburk JW, Staerkel GA, Busaidy NL, Clayman GL, Evans DB, Perrier ND: Clinical significance of distinguishing between follicular lesion and follicular neoplasm in thyroid fine-needle aspiration biopsy. Ann Surg Oncol; 2009 Nov;16(11):3146-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of distinguishing between follicular lesion and follicular neoplasm in thyroid fine-needle aspiration biopsy.
  • BACKGROUND: Subclassifying indeterminate thyroid fine-needle aspiration (FNA) biopsy findings as follicular lesion or follicular neoplasm has been suggested as useful in triaging patients to observation or surgery, respectively.
  • The purpose of this study was to evaluate a single institution's experience with indeterminate thyroid FNA results to determine if subclassification (neoplasm versus lesion) aids in identifying patients at higher risk for malignancy.
  • METHODS: From 1990 to 2006, all patients with indeterminate thyroid FNA results (follicular lesion or neoplasm) at The University of Texas M.D.
  • Patients with FNAs suspicious for papillary thyroid carcinoma or with definitive malignant disease (i.e., metastases) were excluded.
  • RESULTS: Indeterminate FNA results were present in 540 patients, including 410 as follicular lesion and 130 as follicular neoplasm.
  • Two hundred ninety-seven (55.0%) patients underwent surgical resection: 199 (48.5%) follicular lesions and 98 (75.4%) follicular neoplasms.
  • Incidence of malignancy was higher in thyroid nodules classified as neoplasm compared with lesion (21.4% versus 7.0%, respectively; P=0.0005) and increased in follicular neoplasms with nodule size (37.5% malignant if nodule was [4 cm, P=0.03).
  • CONCLUSIONS: Subclassification of indeterminate thyroid FNA biopsy results into neoplasm and lesion successfully defines high- and low-risk nodules, respectively.
  • These findings support surgical resection for follicular neoplasms, selective use of surgical intervention for follicular lesions at our institution, and continued efforts to define unified terminology between institutions.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727961.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Liu J, Singh B, Tallini G, Carlson DL, Katabi N, Shaha A, Tuttle RM, Ghossein RA: Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer; 2006 Sep 15;107(6):1255-64
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity.
  • BACKGROUND: There is continuous debate regarding the optimal classification, prognosis, and treatment of the follicular variant of papillary thyroid carcinoma (FVPTC).
  • The objective of this study was to assess the behavior of FVPTC, especially its encapsulated form, and shed more light on its true position in the classification scheme of well differentiated thyroid carcinoma.
  • METHODS: All patients with FVPTC, follicular thyroid adenoma (FTA), and follicular thyroid carcinoma (FTC) who were diagnosed between 1980 and 1995 were reviewed and reclassified according to the currently accepted definition of FVPTC.
  • CONCLUSIONS: FVPTC appeared to be a heterogeneous disease composed of 2 distinct groups: an infiltrative/diffuse (nonencapsulated) subvariant, which resembles classic papillary carcinoma in its metastatic lymph node pattern and invasive growth, and an encapsulated form, which behaves more like FTA/FTC.
  • [MeSH-major] Carcinoma, Papillary, Follicular / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Papillary / pathology. Adolescent. Adult. Aged. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Models, Biological. Neoplasm Invasiveness. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16900519.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Liu FH, Liou MJ, Hsueh C, Chao TC, Lin JD: Thyroid follicular neoplasm: analysis by fine needle aspiration cytology, frozen section, and histopathology. Diagn Cytopathol; 2010 Nov;38(11):801-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid follicular neoplasm: analysis by fine needle aspiration cytology, frozen section, and histopathology.
  • We performed a retrospective analysis of follicular neoplasm data obtained from frozen section examinations of thyroid nodules.
  • Patients with papillary thyroid microcarcinoma were excluded from this study.
  • In 971 cases, frozen section examination was performed during the surgical treatment of follicular neoplasm that was diagnosed via FNAC.
  • Thyroid malignancies were histologically confirmed in 25.1% of cases (244/971).
  • Among the patients with papillary thyroid carcinoma, 45 were diagnosed with the follicular variant of papillary thyroid carcinomas (27.4%).
  • The diagnostic sensitivity of frozen section for the nonfollicular variant of papillary thyroid carcinoma was better than that for the follicular variant of papillary thyroid carcinoma (89.1% versus 78.9%; P = 0.1023).
  • For 12 cases the diagnosis was atypical follicular adenomas.
  • The diagnostic accuracy of frozen section in cases of follicular neoplasm was 76.9% with a sensitivity of 84.8% and a specificity of 98.9%.
  • In conclusion, our analysis revealed high rates of accuracy when using frozen tissue sections for early diagnosis and treatment of follicular neoplasm; thus, an early decision to extent of surgery prevents a risky follow-up surgery.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Frozen Sections. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 Wiley-Liss, Inc.
  • (PMID = 20014303.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Eberhardt NL, Grebe SK, McIver B, Reddi HV: The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol; 2010 May 28;321(1):50-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.
  • When identified at early stages, most well-differentiated thyroid cancers are readily treated and yield excellent outcomes.
  • Follicular thyroid cancer (FTC) however, when diagnosed at a late stage, may be very resistant to treatment, and exhibits 10-year survival rates less than 40%.
  • Despite substantial progress in recent years, we still have limited understanding of the molecular and biological interrelationships between the various subtypes of benign and malignant follicular thyroid neoplasms.
  • In contrast to the wealth of information available regarding papillary thyroid carcinoma (PTC), the triggering mechanisms of FTC development and the major underlying genetic alterations leading to follicular thyroid carcinogenesis remain obscure.
  • Recent studies have focused on a chromosomal translocation, t(2;3) (q13;p25), fusing PAX8, a transcription factor that is essential for normal thyroid gland development, with the peroxisome proliferator-activated receptor gamma (PPARgamma), a member of the steroid/thyroid nuclear receptor family.

  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Thyroid. 2006 Nov;16(11):1091-6 [17123335.001]
  • [Cites] Pharmacol Rev. 2006 Dec;58(4):726-41 [17132851.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1161-70 [17317825.001]
  • [Cites] Thyroid. 2007 Jun;17(6):497-509 [17614769.001]
  • [Cites] Curr Mol Med. 2007 Sep;7(6):532-40 [17896990.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Nov;67(5):706-11 [17651453.001]
  • [Cites] Cell Cycle. 2007 Nov 15;6(22):2817-25 [18032931.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jan;93(1):278-84 [17989125.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov;265(1):265-71 [10548525.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] Science. 2000 Oct 6;290(5489):138-41 [11021799.001]
  • [Cites] Cancer J. 2000 Mar-Apr;6(2):50-7 [11069217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13144-9 [11069301.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5590-7 [11114739.001]
  • [Cites] Thyroid. 2001 Apr;11(4):339-51 [11349832.001]
  • [Cites] Nutr Metab Cardiovasc Dis. 2001 Feb;11(1):64-9 [11383325.001]
  • [Cites] J Mol Endocrinol. 2001 Aug;27(1):1-9 [11463572.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6105-11 [11507060.001]
  • [Cites] Adv Anat Pathol. 2001 Nov;8(6):345-54 [11707626.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):48572-9 [11679588.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52 [12161538.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1016-23 [12170088.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1053-60 [12651598.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] Oncogene. 2003 Jul 10;22(28):4406-12 [12853977.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3634-41 [15077183.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):375-8 [8536638.001]
  • [Cites] Endocrinol Metab Clin North Am. 1995 Dec;24(4):761-801 [8608779.001]
  • [Cites] Surg Oncol Clin N Am. 1996 Jan;5(1):43-63 [8789493.001]
  • [Cites] Curr Opin Lipidol. 1997 Jun;8(3):159-66 [9211064.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3684-91 [9360526.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):525-30 [9467569.001]
  • [Cites] Nat Genet. 1998 May;19(1):83-6 [9590296.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5523-8 [9850089.001]
  • [Cites] Recent Results Cancer Res. 1998;154:265-70 [10027006.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Oct 14;264(1):93-9 [10527847.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2004 Nov;4(6):465-77 [15579013.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):1068-81 [15761501.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4238-45 [15899815.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):309-20 [15947883.001]
  • [Cites] Thyroid. 2005 Jun;15(6):594-9 [16029127.001]
  • [Cites] Endocrinology. 2005 Oct;146(10):4456-63 [16002527.001]
  • [Cites] Endocrinology. 2006 Jan;147(1):367-76 [16179407.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):1143-9 [16352687.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Apr;58(1):1-14 [16388966.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1785-93 [16551863.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2304-17 [16331265.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):485-95 [16728576.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:29-53 [17119192.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Endocrinol Metab Clin North Am. 2008 Jun;37(2):375-87, viii-ix [18502332.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2194-201 [18381570.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6578-86 [18701481.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7156-64 [18757431.001]
  • [Cites] Hum Pathol. 2008 Oct;39(10):1540-7 [18602667.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):687-94 [19147585.001]
  • [Cites] Endocr Metab Immune Disord Drug Targets. 2009 Mar;9(1):76-83 [19275683.001]
  • [Cites] Hum Pathol. 2009 Jun;40(6):827-33 [19200582.001]
  • (PMID = 19883731.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA080117-08; United States / NCI NIH HHS / CA / R01 CA080117-08
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PAX8-PPARgamma fusion protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors
  • [Number-of-references] 85
  • [Other-IDs] NLM/ NIHMS161308; NLM/ PMC2849860
  •  go-up   go-down


96. Jakubowski M, Hunt JL: BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns. Am J Surg Pathol; 2009 Nov;33(11):1590-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns.
  • BACKGROUND: Current literature suggests that up to 60% of papillary carcinomas have mutations in the BRAF gene.
  • However, follicular variant of papillary carcinoma has a much lower frequency of mutation.
  • Tumors with mixed patterns of growth, including distinctive area of follicular and papillary growth, have not been well studied for the presence of the BRAF gene mutation.
  • DESIGN: Cases of papillary carcinoma were identified with well-defined conventional papillary growth pattern, alongside other areas with follicular growth pattern.
  • In comparing the follicular and the papillary growth patterned areas, the BRAF mutation was concordant in all cases.
  • Four cases had an additional separate focus of microscopic papillary carcinomas.
  • CONCLUSIONS: Papillary carcinomas of the thyroid with papillary growth and areas of follicular growth have a high frequency of BRAF mutations.
  • The BRAF mutational profile is identical in the follicular areas and in the conventional papillary growth areas.
  • These molecular data support the common diagnostic decision that a tumor with any amount of conventional papillary growth should be designated as a conventional papillary carcinoma, regardless of the presence of follicular growth pattern areas.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Papillary / genetics. Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19738460.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


97. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY: Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol; 2007 Feb;14(2):730-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging.
  • BACKGROUND: Papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) are two distinct histological types of thyroid carcinoma but have often been studied and staged as a collective group, known as differentiated thyroid carcinoma (DTC).
  • RESULTS: There were statistically significant differences between PTC and FTC in terms of age >/=50 years at diagnosis (P = .040), tumor size (P < .001), lymph node metastases (P < .001), distant metastases (P < .001), extrathyroidal extension (P < .001), multifocality (P = .002), capsular invasion (P < .001), extent of thyroid resection (P < .001), radioiodine ablation (P < .001), and external-beam irradiation (P = .003).
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Papillary / pathology. Neoplasm Staging / methods. Thyroid Neoplasms / pathology


98. Carvalho GA, Graf H: [Anaplastic thyroid carcinoma]. Arq Bras Endocrinol Metabol; 2005 Oct;49(5):719-24
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaplastic thyroid carcinoma].
  • [Transliterated title] Carcinoma indiferenciado de tireóide.
  • Well-differentiated thyroid carcinoma (TC), as papillary and follicular carcinoma, usually follows a relatively benign course after total thyroidectomy and thyroid remnant ablation with 131I.
  • In contrast, anaplastic TC or undifferentiated TC, also derived from the thyroid follicular epithelium, refers to one of the more aggressive human malignancies, which have lost most or all characteristics of the tissue from which it originated.
  • [MeSH-major] Carcinoma. Thyroid Neoplasms
  • [MeSH-minor] Combined Modality Therapy / methods. Disease Progression. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444354.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 30
  •  go-up   go-down


99. Nosé V: Thyroid cancer of follicular cell origin in inherited tumor syndromes. Adv Anat Pathol; 2010 Nov;17(6):428-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid cancer of follicular cell origin in inherited tumor syndromes.
  • Well-differentiated thyroid cancer accounts for 95% of thyroid malignancies.
  • In contrast to medullary thyroid carcinoma, in which about 25% are familial, only 5% of follicular cell-derived thyroid carcinomas are a component of a familial cancer syndrome.
  • The familial follicular cell-derived tumors or nonmedullary thyroid carcinoma encompass a heterogeneous group of diseases, and are classified into 2 distinct groups: syndromic-associated tumors, occurring in syndromes in which nonmedullary thyroid carcinomas are the predominant tumor encountered, and nonsyndromic tumors, those occurring in tumor syndromes in which thyroid involvement is a minor component.
  • Other syndromes, as McCune Albright syndrome, Peutz-Jeghers syndrome, and Ataxia-teleangiectasia syndrome may be associated with the development of follicular cell-derived tumors, but the link is less established than the above syndromes.
  • The second group of familial follicular cell-derived tumors syndromes or nonsyndromic tumors, in which nonmedullary thyroid carcinomas are the major findings, include pure familial papillary thyroid carcinoma, with or without oxyphilia, familial papillary thyroid carcinoma with papillary renal cell carcinoma, and familial papillary thyroid carcinoma with multinodular goiter.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Neoplastic Syndromes, Hereditary / pathology. Thyroid Neoplasms / pathology


100. Miller MC, Rubin CJ, Cunnane M, Bibbo M, Miller JL, Keane WM, Pribitkin EA: Intraoperative pathologic examination: cost effectiveness and clinical value in patients with cytologic diagnosis of cellular follicular thyroid lesion. Thyroid; 2007 Jun;17(6):557-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative pathologic examination: cost effectiveness and clinical value in patients with cytologic diagnosis of cellular follicular thyroid lesion.
  • OBJECTIVE: Routine use of intraoperative pathologic examination (IOPE), including frozen section (FS) and scrape preparation cytology (SPC), during diagnostic thyroid lobectomy continues to be a source of controversy.
  • We sought to better delineate the usefulness and cost-benefit ratio of IOPE in the context of cytologically diagnosed cellular follicular lesion (CFL) or follicular neoplasm (FN).
  • MAIN OUTCOME: IOPE correctly identified 3 of 16 follicular carcinomas and 9 of 36 papillary carcinomas.
  • On univariate analysis, malignancy risk among follicular nodules did not correlate with age, gender, or nodule size.
  • [MeSH-major] Cytological Techniques / economics. Intraoperative Period. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / surgery. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / pathology. Carcinoma, Papillary, Follicular / surgery. Cost-Benefit Analysis. Female. Frozen Sections / economics. Humans. Male. Middle Aged. Thyroidectomy / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614777.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement